<SEC-DOCUMENT>0001193125-15-254322.txt : 20150716
<SEC-HEADER>0001193125-15-254322.hdr.sgml : 20150716
<ACCEPTANCE-DATETIME>20150716073100
ACCESSION NUMBER:		0001193125-15-254322
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150716
FILED AS OF DATE:		20150716
DATE AS OF CHANGE:		20150716

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15990527

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d18512d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 16&nbsp;July 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18512tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">423 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ian Phillips</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANISINA RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR NEUROBLASTOMA</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16&nbsp;July 2015, Sydney AUSTRALIA:</B> US-Australian drug discovery
company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.<B></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan Drug Designation encourages the development of experimental drugs for clinical
indications that do not have a high incidence and has been instigated in a number of territories including the U.S, Europe and Australia.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan Drug Designation can provide the following benefits to a drug developer:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility for US government grants to defray clinical trial costs</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Tax incentives for
clinical research conducted in the United States</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Waiver of US prescription drug filing fees</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Enhanced marketing
rights upon Market authorization.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina was granted Orphan Drug Designation for
neuroblastoma under the U.S. Orphan Drug Act following a review by the FDA of a package of pre-clinical data submitted by Novogen.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The data is from preclinical studies which were done as part of the Children&#146;s Oncology Drug Alliance (CODA) involving Australian charity, The Kids&#146;
Cancer Project (Sydney), The University of New South Wales (Sydney), The Nationwide Children&#146;s Hospital (Columbus, Ohio), and Novogen. The key findings from these studies showed that Anisina significantly improved the effectiveness of the
standard of care microtubule targeting compound, vincristine, in an animal model of neuroblastoma. The data from these studies were recently announced and presented at Eighth Annual Cancer Molecular Therapeutics Research Association (CMTRA) meeting
in Boston, USA.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Interim Chairperson, Ian Phillips said &#147;Obtaining the FDA approved Orphan drug designation for Anisina is an
important strategic achievement for us. It demonstrates the company&#146;s commitment to bringing a drug to market which we hope will improve the outcome for children with neuroblastoma. These incentives provided by the FDA have the potential to
offset those significant costs associated with the clinical development of Anisina.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM program director, Dr Justine Stehn said, &#147;Given it
is our intention to take this drug through to the clinic to treat childhood cancer, the designation affords additional guidance from the FDA in the design of our clinical trial program enhancing the efficiency and innovativeness of Anisina&#146;s
development.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Researchers have demonstrated efficacy in an animal model of neuroblastoma both as a monotherapy and in combination with vincristine
as stated in the company&#146;s announcement earlier this month and Novogen is now conducting pre-clinical studies to further validate the combinatorial effect of Anisina with a range of microtubule-targeting compounds in animal models of adult
cancer. Once the company has completed its pre-clinical toxicology program for Anisina, the drug is expected to enter the clinic for adults in mid-2016 with clinical trials in childhood cancer in Australia and the United States to follow in early
2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18512footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18512header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Orphan Drug Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan Drug Designation is granted to a drug or biological product when it is to treat a rare disease or condition and there is a scientific rationale that
supports its use in that disease or condition. &#147;Rare&#148; is defined by the number of people that have the disease (prevalence) and is under 200,000 in the USA. The sponsor or company developing the new drug, requests Orphan Drug Designation
from the FDA or local regulatory authority, as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Orphan Drug Act (ODA) in the USA provides the sponsor of the drug with various incentives
to continue developing the drug, including tax credits for qualified clinical testing, a waiver of the marketing application and a period of market exclusivity. Importantly, the FDA also offer extra guidance and consultative opportunities during the
development period as explained on their web-site. Other regulatory regions, such as Europe and Australia, have similar orphan drug designation and incentive schemes that Novogen intends to access in due course.
<U>http://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/default.htm</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Neuroblastoma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuroblastoma is a cancer that is most frequently observed in the young with more than 90% of diagnoses occurring in children under 5
years of age. It is considered to be the most common solid tumour in children outside the brain. Although childhood cancers such as neuroblastoma are relatively rare compared to adult cancers, the potential years of life lost are substantial making
it imperative that new clinical strategies are developed to treat this disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Anisina </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina is a small molecule which belongs to a family of compounds termed the anti-tropomyosins or ATMs. Anisina has been designed to inhibit a protein known
as Tpm3.1. Tpm3.1 is a structural protein and is a core component of the skeleton, or cytoskeleton of a cancer cell. By binding to Tpm3.1, Anisina impacts the function of this structural protein causing the collapse of the cytoskeleton which results
in the death of the cancer cell. Anisina has been shown to be effective against a broad range of cancer types. At Novogen we are focused on the clinical development of Anisina for the treatment of both adult (melanoma and prostate) and pediatric
(neuroblastoma) cancers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a
public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug
technology platforms (the super-benzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that are first-in-class with potential application across a range of degenerative diseases. Given the encouraging data from in vitro and in
vivo pre-clinical Proof-of-Concept studies in the field of Oncology, our immediate focus is to bring our lead Oncology drug candidates Cantrixil, Anisina and Trilexium into the clinic in 2016 pending successful completion of their respective
toxicology programs. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the potential clinical indications being pursued, with the ultimate objective of
employing both technologies as a unified approach to therapy. For more information, please visit <U>www.novogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18512footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18512header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The Kids&#146; Cancer Project </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kids&#146; Cancer Project is an Australian charity dedicated to funding medical research to find a cure for childhood cancer. Thanks to community support
the charity has invested more than $24 million into research and is currently supporting 13 research projects. The independent charity is the largest not-for-profit funder of childhood cancer in Australia. The Kids&#146; Cancer Project was inspired
by one man who promised to find the cure for childhood cancer and make a difference. The Kids&#146; Cancer Project supports research that will increase a child&#146;s chance of survival and that will eradicate or minimise the toxicity of current
treatments children endure. The Kids&#146; Cancer project supports collaborative research that has the greatest chance of clinical success and is excited about the potential that Anisina presents as a potential improvement in chemotherapy treatment.
Visit <U>www.thekidscancerproject.org.au</U> for further information or to donate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Manager </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;2 9472 4109 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section
21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company&#146;s drug development program, including, but not limited to, Anisina, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to Anisina, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Anisina, that could slow or prevent products coming to market, the uncertainty of
patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Anisina, and other risks detailed from time to time in the filings the Company makes with
Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including
those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18512footer.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g18512footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18512footer.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00,:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z1#5$.30Y,$$R0C@T,3%%-3DR-#=%-T)$1CDV
M0S,Y,S,B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z1#5$.30Y,#DR0C@T
M,3%%-3DR-#=%-T)$1CDV0S,Y,S,B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HX.&(R.&$P-RTX,#=D+31D,#$M.3(T-2TR
M.31F.39D-V4Y,3DB('-T4F5F.F1O8W5M96YT240](G5U:60Z86$Y9CDR934M
M8S@W9"TT-&8Q+6%F93DM,&%F.3DT8C%F9C<R(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C4P-3DU-#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(#$M,RYD;V-X
M/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<`5H``QLE1QP"
M```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N``Y!9&]B90!D
MP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`@$!`@("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`#H"Q@,!$0`"$0$#$0'_Q`#*``$``@(#`0$!````````````
M!08$!P(#"`$)"@$!``(#`0$!``````````````0%`0,&`@<($``!`P,`!0@#
M"@@-`P4````!``(#$00%(3%1$@9!87&1,A,S!X$4-:&Q(D)28I(T-@C!<H*R
M(T-C<_"BPE.#LR1$=+05=3>$%G;19$4F1A$``@$#``0+!`<$"@,!``````$"
M$0,$(3$R!4%187&!D:&Q$C,&P2)R--%"8K(3-0?A@B-S\%*2HL)#@Q1$%?%T
M)3;_V@`,`P$``A$#$0`_`/[B:G:>LH!4[3UE`*G:>LH!4[3UE`*G:>LH!4[3
MUE`*G:>LH!4[3UE`*G:>LH!4[3UE`*G:>LH!4[3UE`*G:>LH!4[3UE`"XM!<
MYVZT:W$T:.DDT"#4JO44_B#C'AC%V=W'>YJS[P0NK!;R&]FUC]7:B8M-=M%M
MA8O3TQBZ$&_O/`Q_,NQ\7$M+ZE4TAD/.#$P[S<9B[V^<"0V2Y?'90FFIVZWU
MB:AYP"I$<&X]MI+K*B]ZEQXZ,>W.3XW[J]K*-D?-7BB\WFVCK/%QFH`M;<2S
M`$Z/T]R93O`:*AK5)CAV8Z75OE_855[U!O"[HMN%N/(JOK=2C7^7RN4?OY'(
MWEZZM1ZS/)(T$_)83W;?0`I$;<(;*2*J]D7\AUOSE-\K;(Y>C2$`0!`$`0!`
M$!D6UY=V<@FM+F>VE&J2":2%_1O1N:ZBQ*,9*DDFCW"Y<MR\=N3C+C3H^PNN
M/\RN+;"C77\>0C'ZO(P,G-/DB=G<W`'Y14>6)9EP4YBSL[\WE95'-37VE7MT
M/M+SC_..`[K<KA98S0`S8^X9(VM-+NXN1&X`GD[PJ/+!?U)+I+:SZECJR+3Y
MXNO8_I+UCN/^$LEN"/+1VLK]T"'(,?9O#C\7?D'<$UV/(4>6->AI:JN0MK.^
M=VW]"N*,N*7N]^CM+=%)',P20R1S1D5$D,C)6$;0^,N:>M:-6AZRRC*,U6#3
M7(ZG-#(0!`$`0!`$!:L(?[))^^?^;$@)>IVGK*`5.T]90"IVGK*`5.T]90"I
MVGK*`5.T]90"IVGK*`5.T]90"IVGK*`5.T]90"IVGK*`5.T]90&)=W+[=K-T
M`N?6A<31H;2N@$5)0$2^ZN'ZY7`;&_`'\6B`Z*G:=.O3K0"IVGK*`5.T]90"
MIVGK*`5.T]90"IVGK*`\?\5M<_BGB`-:7N.8O]#6ESC^G=R`$E7=E_P8U_JH
M^9[PT[RO+2_XDN\PX,'E+@`LM'L:[2'S;L(IMH^CO<7IWH+A/-O#OW=F#2XV
MZ>VO8<;_`,J\%GQ_]BL,5?$BA+K)LEP*FIW;ND,S/05B&=<LO^$VND\7O3&'
MG?/6[4OW:OHEH:*;D?N]>6V-M;S)6>-NWS6T,EQZO?W]S>6+FQ_"=&VW<YI9
M4=FKG`4U*1'>N9<:A*2HWP))]959/H+T_CVIY-JW)RBJTE)RCHY/_)!6>/L,
M='W-A96ME%_-VL$<##3:(VMWCTK=*<I.LFVR'9L6,>/@L0C"'%%)=QF+R;0@
M"`(`@"`(`@(K)8+"Y=N[E,78WPINAUQ;L?(T:.S+02MU<A"V1N7(;$FB+D8.
M'EJF3:A/G57UZ^TU_DO)[A2\#W63LAB97;Q;ZO<>LV[7'5_9[L2.W!L#VJ5#
M/OQVJ275VHHLGTGNR]5V7<M2?$ZKJE7O1K_)>2N=@WG8O*8_(M%2V.X$MA.X
M<@J?6("[I>T*3#>,'MQ:?)I*'(]'YUO3C7(7%Q.L7[5VFOLGP9Q7AP77^#OX
MX@2._AC];M]`J3WUHZ9@%.4T4N&39N;$E7J[RBR=T[SQ//LW%'C2\2ZXU*Q6
MA(-01K!J".D'2%NTE=7@X030$Z=`J@JSV[Y=?=4P>;P&#XCXHXGR<[<UC++*
MLQ6$@@L8X(;Z&.YBAFR%TV[FED;%(`_<BC&]6AII7.96_+MN[.S9@EX9-5;K
MJ=-6@^R>G_TRP\W!L;PWEDW'^-;C/P6THI*232<I>)MT:K1(]'<.^1GE3PP8
MY+#@['7=U&=YM]FC+FKS>T?"#L@^6!A%-&[&VBJ;N\LZ]HG<:CQ+0NP^A;O]
M%>F-VT=C$MRN+ZURMR7]ZJ70D;6CBCB8V.*-D4;`&LCC:UC&-&IK6-`:UHV`
M*%5MU>LZ>,(12C%)16I+0D63#>!/^]9^85IN:^@EX^IDRUSFG>:XM(Y02#UA
M:R09T>2O(_UI>-5)`'_QC\(=:`EK+)/N9.Z>S==0D.:XTT::%IJ=0VH"4J=I
MZR@%3M/64!\0!`$`0!`$`0!`$`0!`$`_AIT#TGD0&K\YYJ83&3S6EA;S9>XA
M>Z-\L3V06+9&U!#;AP>^<-<*$L9385+MX=R:\4GX4^LH<KU!BV).W9B[LTZ5
MK2->?37H1KK(^:_$]WO-LVV.*83H-O!ZS.!3^>NS(VO.&!2H8=I;56_Z<127
MO4.\+GE^"VN15?6Z]Q1[_-YG*FN1RE_>BM=R>YD=$#I&B$.$+=!Y&J3&$(;,
M4N@JKV3DY#K?N3GSMTZM1`WM!:7%!^J=H`YP3H"]D>E-125@R$`0!`$`0!`$
M`0!`$`0!`$`0&79Y"_Q[^\L+VZLG_*M9Y8"=1T]VYN\-&HU"Q*,9;23-EN[=
MM.MJ4H/D;7<7;'>9W%EC1LMW#DHP`-S(0,>^@V3P]S-7I)4>6)9EJ5.8M+&_
M-XV7[TE./VE[51E\Q?G!8S.9'F,7-9U-'7-E*+J%NH;SH)!'.`.7=+SS*-/!
MDM-MUYRWQ_4EJ34<FVX\L75=*>GJJ;=M;JWO;:&\M)F7%M<1B6":,[S)(W:G
M`\G.-8.A0FG%^&6AHZ.W<A=@KEIJ5MK0T=ZP>P@"`("UX4$6;R=&],_=YQ2,
M5'-5I0$J@"`(`@"`(`@"`(`@"`("-R?9@_+]\(")0!`$`0'%SFM[1I_#F0'4
M9Q\45YSH0'69GG51O1K]U`:>R44;,IDGLCC8^2^N'R/:QK7/>Z0DN>X`%SB>
M4J;%MP2>JAS%Z,5EW*))N3X.4PUDP$!$YWV+E?\`;[K^K6RUYD?B(N=\E=_E
MON9Y]5L<($`0!`$`0!`$`0!`$`0'T$C42.@H"%R7#F`S%?\`4\/CKUQ%.\FM
M8^_YJ7#`R<4YG+9"[<M[$FNDAY&[\'+^9LVYOC<57K6GM-?93R;X6O-YUA+D
M,0]PT"&87=N/Z&[#Y*<FB0*5#/OQVJ275W%%E>DMVW:RL.Y:ER/Q+JEI[3]`
MN"<0_&\%\)X]LS9Q9<.8>U$I;W1D[BP@CW]PN>&[V[6E31<QD2\>3<GPN;?6
MZGW3<^*\7=6+93\7@Q[<:ZJTBE7L+"]KF'=>-T\E>7HVK26.IT9Q0%BPW@3_
M`+UOYA6JYM=!)L:F2ZUD@("2Q7UH?BN_-*`LR`(`@"`(`@"`(`@"`(`@/H!<
M:-!)V`$GJ"!)O41%SG\!97++*]SV$L[QYW66EWE\?;7+G?)$$URR7>TZJ+VK
M=R2\48R:YF1KF;A69JU=O68W'P.<4^INIG77PK&ZD:0Z-]G<N9(PAS'CN)*.
M8]M6N'."O,=I+AJC;<=;,I+5X):>AGB1NH>CW@K\^60V3DAZ"`^(",FQ-K*2
MYH=$XU)W#\&I^::@>BBR-)&RX28:8I(WC8ZK'<GXS?=0:3`EL;J'2Z&2G*0W
M>'6VH6!4Q.;E"`(`@"`(`@"`(`@"`(`@"`(`@/4WEK]CL;S37X',/6WZ.A5&
M7Y\NCN.]W#^5PYY?>9>U&+@[X[6XF\.&1XVAAW=O:(#4!(QX6Z?3O'1Q`BNE
MQ>X>A@(]U`2,6&MF4,CWS'8?@,U\H;5QKTH"5:UK&AK&AK6BC6@4``Y``@.2
M`(`@"`(`@"`(`@"`(`@(W)]F#\OWP@(E`$`0!`84G;=TH#@@"`U-E/:5_P#X
MR?\`/*F1V5S',W_FI_$^\P%Z/(0$3G?8N5_V^Z_JULM>9'XB+G?)7?Y;[F>?
M5;'"!`$`0!`$`0!`$`0!`$`0!`$!?L/YD<2XB"WL^\M;^RM6-BB@O(/ALA8`
MUD3+F!T4H:QH`%=Z@"C3Q+4Y.6E29=XGJ#>.)!6DXSM1224EI27!54?74F\S
M]X#A_A_&1W_$V&R5M`Z\MK4S8HQ9'NY)VRG?,$S[281M[O3NE[N8K7#==V]/
MP69)RI73H)F5ZXP<&Q&_O*S<C!S4:PI+2ZM:&XO@Y2<X>\Z_*SB<1MQO&>(A
MN)>S8Y>5V%O:UINF')MMFN<3JW7.JM5W=^;9V[<J<:]Y=A/W?ZR],[S26/EV
MHW7]6;_#EU3\/8V;QP#X[FVEDMI&7$;Y&%DEN]LS'@L-"U\1<UP/,56W4U*C
MT.AUN+.$X.<&I1?"FFNM%GCQUY**B%S6TKO248.IU">I:R49T>'.@RS`;6QM
MK_&<1[R`DK>RM[8[T;7%]*;[G$FAYA1ON(#+0!`$`0!`$`0!`$`0&E_,WSTX
M1\KKV#$Y6TS&5S5S91Y"/'8R"%C&6DTDL4,MQ?W<L5O%WDD#J-:)'4%2!H4[
M%W?>RXN<'%03I5_0CEM_>KMV^G[JQLB-VYE2@I*,$M3JDW)NBTIZ-+/,?$'W
MP.++LOCX8X8PF#B(`9<Y.6XS=\#RNW&G'V3:CD+'TVJUM;FLQTW92D^30O:S
M@LW]2]XW&XX%BU:CQS;G+_#'L9HSB+SB\SN*M]N7XTS7J[Q0V6-N!AK&E2:>
MK8IMHQ^NE7[QIRJ?:PL6SIA"->-Z7VG)9OJ??^\*K)RKOX;^K%^"/5#P]IK1
MX$CG22?I)'G>>^3X;WN.DN>]U7.<3RDU4K5J*)KQ.LM+99L1QUQIPM!-_P!O
M<4YW$L9!-2WM<C<"S([MY+76,CY+-[#72#&05IN8]B[YD(M\=-/7K)^-O?>F
M[X/_`&61>MQH]"D_#_9;<>PUW@_O,>86.$3,I#A.((6T#S<V;L?=N;O:3ZSC
MGQ0[]-%3"Y2KF[,>6QXHOGKWD'&]:[VQWX;ZMWH+C7A?7&B[&;OX3^\IPOG\
MA88G*87+8.]R-U;V-O*Q\&4Q[KJZE9!;L?+%ZO=0LDED`WC"0VNDTTJ#=W;=
MMQ<X24HI5XG_`$Z3I]W^M<',O0Q[UJY:N3DHK5*-6Z+2J/IH>D#H)!U@T/2%
M7'9U1\6!4^H`@"`Z9+>"7Q(HWUY2T5^D/A(*$?)A[5]=PR1'DW2'-ZGU-/2@
MYB.EPL[=,4D<@V&K'4]-6U]*R"/EL[F'Q(7@?*`WF_2;4+`J8R`(`@"`(`@"
M`(`@.Z.VGF\.&1X.HAAW?I:``@)&+#73],CHXASG?=U-J/=0'K7RPPMNW@W&
M.EDDD/?7]6BC&?7)1R5=J&U5&7HOR7-W'>[A_+(?%+[S-F16=K#3NX(P1J<Y
MN^_Z3]XJ,7!DH`@"`(`@"`(`@"`(`@"`(`@"`(#HG@9<-`>7#=KND<E=>@Z"
M#1`1[\=(*EDC7;`06D^^-"`Q7VT[.U$_I`WAUMJ@.A`$!A2=MW2@."`(#4V4
M]I7_`/C)_P`\J9'97,<S?^:G\3[R%N;^QL@3=WEM;`:^^F8QW0&$[Y/,!5>X
MQE+939'N9%BRJW9QCSLK-WQS@[?1`ZYOGZJ00F-FK^=G[L4Z`5OCBW9:Z)%=
M<WWAPV/%-\BHNME/R_&UWD;>:SMK2*T@G88I7/>Z>=T;C\-H-&1LWFBFHGG4
MFWC1@U)NK14Y>^+V1;E9MQ4;<M#X73N12%)*<(`@"`(`@"`(`@"`(`@"`(`@
M"`U1YS?8UG^]8_\`J[M3MW_,?NLYGU;^51_GQ[I'E@@'00"-ATJZ/F)^HOW!
MB?\`L;S`;4[K>,,<&@DD-'^@QFC031HKR!<CZC\^W\#^\?H#]'&_^IS5P+)A
M3D]S@XCWBN=/L(0!`$`0!`$`0!`$`0!`$!^<'WM_^3[#_P`/Q'^=RRZ7<WRC
M_F/V'PW]1_\`]!'_`-:'?,\NJV.!"`^M:Y[@QC7/>=3&-+WGH:T%Q0)-NBTL
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M98(7C8Z)A_DU6%*2TIL2M6IJDXQ:YB-FP6/EJ6L?`=L3SNU_$?OM6V-^:UZ2
M+<W=C3V4X\S]CJ1<O#<HTP7,;Q\F5KHW=&\W?:?<6Q9$7K5")/==Q>7)/GT=
MU2)FQ=_!4OMI'-%?A1TE::<OP"2!T@+;&Y"6ID.YBY%O:@VN-:>XP""#0@@C
M6"""/05[(_#3A"`(`@.B6V@F\2)CCM+0'?2%"LBB(^7#6K],;I(CS$/;U.T^
MZL`CI<+<-KW3V2C8:L<?0:M]U9!'RVES#XD,C1MW=YOTFU"P#'H=AZD%3NCM
MYY32.&1Y^:QQ'72@051(18>Z>`7[D0/RG;Q'2UM??0$A'A8&^+))(=C:,'\H
M^ZLC22$=E:PT+((P1\8C>=UNJABAE+!D(#U+Y:?8W&_OK_\`SLRJ,SYA]'<=
M[N'\LA\4OO,OBC%P$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!UOBB?VXV.Z0*
M]>M`8SL?`_L[T9)Y#O#3S.T^Z@(*>T>V5X:YK@'$::M.@[-(0'2+:0Z]T>FO
MO(#N;:M^,XGH%!^%`>+>-\WE_P#NGB2S&0N8[6#,7]O%#$_N6MB9.]@:3$&/
M?\$:=XE7V/9M_A1E32XH^5;VS,J6\+]K\22MJ[))+1H3?$40DN<7.)<XZW.)
M+CTDU)4I*BHM13\-7K/B`(`@"`(`@"`(`@"`(`@"`(`@"`(`@-4><WV-9_O6
M/_J[M3MW_,?NLYGU;^51_GQ[I'EE71\Q/U#^X-]A_,+_`,QQWNX&-<CZC\^W
M\'^(_0'Z.+_Y.<^#_<P^X>\ESI]A"`(`@"`(`@"`(`@"`(`@/._G#Y$8GS0R
ML'$`XENL%F;;&18QK/4HLECKF&WEGE@,L0EMKB"1K[AP<YKR"*?!J%8X>\)8
MD';\*E!NO$SB_4OHVQZAR5FJ_*SDQMJ.RI1:3;555-/3P/H/-$_W5.,[65Y=
ME\1D+5I.X[%]Z+N1NWU?(^J,C=S![U9_]Q8EJ4D^75V5.(E^F^]K;;=VU.VO
MZE?$^B7A7:S$/E#88`C_`%C#Y:20&F_DVSPP$[`(&10'2/E.7I9LKJ]R2IR&
M%Z6QL/YJW=<EPSJEV45.LG;2PL+%@;965K:,I0>KP11$@:-+V-#W>DE:W*4G
M5MLL+6-C652Q"$4N))$C%;7-YWD=I;W%W+W<E66\,D[^R14MB:\@5Y2O#:CK
MHD2(PG=K&TG*5-25>XKEAP#Q1>AKC8"R8[3OW\S+<TV]R.\GTC:P+T[]J*TN
MK(]K=6==2]SPK[3IV:7V%XP_EEZI<VMYD,KWC[:>*X;;V4!;&Y\+VR,:^><[
M^Z7-TT8#3E6B>7XDXQ6OC+3'W'^'.-R]<JXM.B7$ZZW]!M?:=JAG0!`$`0!`
M=4L$$XI-#%*/GL:X^@D5"RI2CJ9XG;MW%2<4URHBYL#82#]&V2W=4Z8WDMZ-
MV3>_`MJOS6O20Y[NQI;-8OD?L9%3<.3MTP7$<HV2-,3NL;[5M61%ZTT1)[LN
MK3;DI<^A^U$5-C+^#MVLI`^-&!*WKC+J+:IP>IHB3Q<FWM0=.-:5V&"=!(.@
MC6#H(Z1K"]$>O!PA`$`0''=;6NZ*[:"J`Y(`@"`(`@"`]2^6GV-QO[Z__P`[
M,JC,^8?1W'>[A_+(?%+[S+XHQ<!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!
M]&L=(]]`0<_C2?CN]]`=2`(#4'&7E#BN);VXRV/O7X;*71,ET#%ZS87<Y&F:
M2'?9+;S2'M.82':]VNE3;&;.U%0DJP76<UO/TUCYUV638F[61+2]%8R?'36G
MQTZC3F3\FN-L?O/MK>RS$302'8Z[8)G`;+:\%M(7'8W>4^&?CRUMQ?*OH.8R
M/3&]K%7",+L?LO3U2HS760Q&5Q+RS*8R_P`<X&G]MM)[=I.QKY6-8[1L)4F%
MR%Q5@TT4E['R,9TR+<[;^TFN\CM>K2O9I"`(`@"`(`@"`(`@"`(`@!(&LTZ4
M!*V6#S&1+?4L9>3M=2D@A<R&AII,TNY$&Z==5XE=MPVFD2;.'E7_`"K<VN.E
M%UNB+7:^7&=G&]<36-E\U\C[A_-40-+!](J/+-MK93?86-O<.;/3<<(=-7V:
M.T^W7EQG(16WN+"]/(QDDD$A.QHF8&$_E!(YMIZTT9N;AS(^5*$WQ5:?;])K
M3CSR<\R^,\)'A.'^%;RYOO\`5;.X+KF>SQ]DV")EPV28WU[<06Q8TR#LN<XU
MT!3<3/Q+%W\2Y->'POC;ZCG=^^E]_P"],18F'C3=U78O2XQC1*57XI-+J9U\
M*?<.XWO9(9>-.+^'^';4FLUIA([GB#*!M`=ULLK,=C8Y*Z"=^4#85LO>HL>*
MI8A*3Y="]K(.[?T@WM=<9[TR;-BWPJ"=R?;X8KGJ^8_0;RT\LN%/*?AJ/A?A
M*UFBM3,;S(7UY*)\CE\B^-D4E_?SAK&&1S(PUC&-;'$P!K0`N;R\N]FW?Q;[
MT\"6I+B1]HW#N#=OIS`6[]VQ:MU\4I-UE.7#*3X^)))):$J&P%%+H(`@"`(`
M@"`(`@.#Y&1BKW!M=6T]`&DH#%=?,'88YW20T?A*`QW7DSJTW6#F%3UNJ@,=
MSWO[3G.Z22.K4@."`(#XX![2QX#V'6QX#F'I:X%I0PTFO"]ED#-PKPS<3=_/
M@,3)-6I>;.)M3M<U@:QWI!6U7KRT*4J$26[L"<O'*S;<OA1+-M[>TMI8K2W@
MM8Q#*!';0QP,IW;OBQ-8%XJW)-Z74D*W;M6W&W%1C1Z$DNXTT[7Z![RF'.,X
MH8"`(`@"`(`@"`(`L`Z9;:WG%)H(I.=\;2[3\ZF\.M>U.2U,USM6KFW&+YT1
M<V`L)*F,2P./R'[S0?Q9`[1Z0MBR)K71D2>[<>6F%8ODU=3(J;ARX;I@GBF'
MR7@Q._EMKZ0ML<B+VE1D.>[+J\N49<^C]A"W-I<6C]RXB=&3V2:%KOQ7@EKN
MM;HRC+9=2%=LW;+I=33[.LQUDU!`$`0'QQ#6E[B&,&M[B&L'2YQ#0G)PAM+2
M]"#2'-#V$/8=3V$.:>AS26E9"::JM*/JP#U+Y9_8W&_OK_\`SLRJ,SYA]'<=
M[N'\LA\4OO,OBC%P$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!PEDB@C=-/+%!
M"T$NFGD9#$T`5)=)(YK&@#:42;=%I9B4HP7BFTH\;T(U[F/-KR\P3W1W?$UE
M<W##IM<4V7*S;P%=VMDR6`./.\:5*MX65<V8-+C>CO*7)]1[EQ'X;E^,IK@A
M6;_NU7:5:Z\T+.X8VXQF,NGLN6-GA?D'-M#N2MWF;]O'WT@-#I&\%E8DDZ2:
MKR&M[^M3@KEBW)QDJKQ>[KY-+*Q=<=\17!/=SP6;=-&VULS>`/[2?OGU`6Q8
M]M:U4@W-[YL]345R+VNIA1\8<2QNWAEIWZ:[LL=O(P]+714HO7X-JE*&I;SS
MDZ_B-]"^@L%GYC9.*C;ZSM;MN@%\1?:R\YT=[$XD?-"UO&@]EM$RUON_'1=A
M&2Y-#]J+79\?X&XW1<>M6#SK$T/?1`_O8"\TZ6A:7CW%JHRQM;YQ)[?B@^55
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M;>6L]MJ-#0RL:UPKR@D*5&<9JL6F4MVQ?QY>&_"<)?:37>82R:@@"`(`@"`S
M[#&9')O='C[*XNW-IO\`<LJR.NKO)#2-E><A>9W(6U6;21NLX]_)EX;$)3:X
MM72]2+A9>7.=N*.NY+/'L.L/E-S,!R`1P`LJ>=X4:6;:6S5LM+6XLRYYCA;7
M*ZOJ7TEMLO+;$0@&^N[R^?K+6%EI%T;L?>2G3\\*-+-N/9219VMP8L?.E.;_
M`+*]K[2\XSA"QM@TX[!0-+:?IWP!SR:=HSW6\\GH*CSOW);<F7./NJS;\BS%
M<K6GKD6R'AZZ>`9YHH0/BMWIG4V"@:P=:T.:6HLXX-Q^8TEU_L).'`64=.]=
M+.=?PG=VWZ,=#3TE>7-O42(85F.U61*Q6MM`*0V\,?.V-N]](@N]U>6V]9)C
M;MPV8I=!E,U^C_T6#V9;+F>.FY*\`<E26_1-0@,QF4G;VVLDZ!N'W*CW$!FL
MR=N[MA\9IRC?%>ENFGH0&;'-%*"8WM?370Z1TC6$!V(`@"`(`@"`^C6.GEU>
ME`1%WXSNUV6Z]7)J^;^%`8J`(`@"`(`@"`XO[$G9\.3M=GL.[7S=JRM9AZGS
M&E']MVK6=79UGL_-V<RF\!S+UG!#`0!`$`0!`$`0!`$`0!`$!#<0>S3V/&B[
M>O6?!^?MYJK=8VROWE\MP;2Y^@HZF%$$`0'3<>!-]8\-WU7ZSJ_N_P"UV<Z]
M+6M72>)[+VM7!KZ.4\>>9_UE_P#R/XA^U'LG_IN;Y/,KK$_TOW=9\_WWMOYS
M_4V1Y7_6F?\`(W;_`/S'LKLGZU_#4L9>I^5TZS&Y/,7S>M>5L])["@\&+ZSX
M;?K7UC5^O_;?*YU3/HZ#Z##4MK5P^WE/6?EW]CL/X/8N/`U?6I_%_P#<?+^<
MJ7*^8EKZ3Z%N3\NMZN'5S\/+^TNJCEL$`0!`$`0!`$`0!`$`0!`$`0!`$`0!
M`8>0^I7/M#PW>R?:7_2?M=B]1VN#IU&J_P"3+:U?5VN@\%>:GM)W_(WBN^W7
MU34/J?S?P+H\34O*U?4/D'J#S7\_K_Y&KH]G(63R[[$/V"U?W7VUV1J_:;5$
MS=;\[IV2Z]/[*^0UK9\PW3DOJ;/97A__`"?XKO#YU7V]?#T'896Q_E:OKFLI
M_%?X&O\`NW@?T?,I:U</3K.;N;;V=?!JZ#J63R$`0!GB-UZV^'XNOXG/LYT,
M+:7LU]!N_A/PF?:CLCVK]2[(\/FV>A0+FOZG0=7NW9_Y'#M[/07=:"V"`P<Q
M[.G]F>$_V[[+U?K_`)B]0VN'HUFG*\A^7K_S-CI/%7&WM$_8SMO^Q_@_T_X.
M=7^/J_S/WCY9O;SO^-K?D:NDI2WE6$`0!`$,F\O+;[/R=CVC<=GM>'#XG\GF
M55F>;T'7[@_+W\;U>WV%_P"7EY.C6HI=(MF(Y/9?]']:U^^M,NDM<74O+Z-9
J9#KY?3K7@G'Q`$`0'-FOT?A"`[4`0!`26+^LG7X,GX-:`GD`0!`$!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g18512header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18512header.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00,:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z13(R,4-$,C(R0C@T,3%%-3@Y13%$-3%%1#E$
M,$(V,C(B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z13(R,4-$,C$R0C@T
M,3%%-3@Y13%$-3%%1#E$,$(V,C(B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HX.&(R.&$P-RTX,#=D+31D,#$M.3(T-2TR
M.31F.39D-V4Y,3DB('-T4F5F.F1O8W5M96YT240](G5U:60Z86$Y9CDR934M
M8S@W9"TT-&8Q+6%F93DM,&%F.3DT8C%F9C<R(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C4P-3DU-#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(#$M,RYD;V-X
M/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<`5H``QLE1QP"
M```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N``Y!9&]B90!D
MP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`@$!`@("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`#X"Q@,!$0`"$0$#$0'_Q`#)``$``@(#`0$!````````````
M!08$!P$#"`()"@$!``(#`0$!``````````````0%`0,&`@<($``!`P,!!00$
M!PP)`P4!```!``(#$00%(3%1$A,&09$4!V%Q@2*AL3)"<Q4(4G*2HK(C,T-C
M-+06P=%B@E,D=#4V\,)U@[-%)G8W$0`"`0,!`P@&!0L"!`<``````0(1`P0A
M,1(%05%A<9&A,@:!L<$B$Q31X4(S-/!28G*RPB-S%34'DJ*"0U.SHR1$5'06
M-O_:``P#`0`"$0,1`#\`_N)J=Y[R@%3O/>4`J=Y[R@%3O/>4`J=Y[R@%3O/>
M4`J=Y[R@%3O/>4`J=Y[R@%3O/>4`J=Y[R@%3O/>4`J=Y[R@%3O/>4`+N%I<Y
MW"T;7.=PM'K<2`$#:2J]$4[/]:]+XNTNF7F:M'2"(U@M7NO9MHTX+42AI]9"
MW0L7IZQBZ=A`O\4X?CZ7+L=[F6K[JFD,AYP8J'B;C<5>7K@2&R74D=E$:=O`
MT7$U#Z0TK?#!F_&TEVE3>\RV(Z8]N4G^DU%>UE&R'FKU1=ES;5]GC(R"`+6W
M$DPJ?\>Y=,>(#M#6J3'#LQU=6^GZBJO<?XA=T@X6X_HK7M=2CW^7RN4?QY'(
MWEZZM1XF>21H.OR6./+9M[`%(C;A#PI(JKV1?R'O7YRF^ED<O1I"`(`@"`(`
M@"`R+:\N[.436ES/;2MV20321/']Z-S746'&,E2231[A<N6I;]N3C/G3HRZ6
M'F5U;84:;^._C'ZO(P,N#2E*<]G*N*?WBH\L2Q+DIU%G9XWQ*RJ.>^OTE7OT
M?>7FP\XX31N4PDC-`#-C[EKQ6FIY%R&$:_M"H\L%_8EVEM9\RK9D6GUQ?L?T
MEYQ_F#TED>!K,JRTE=0<K(1OM'!Q^;S'@VYUTT?11Y8M^.N[5=!:V>,\.O:*
MXHRYI>[W[.\M\4T-PP26\L4\9%0^"1DS"-_%&YS:+0ZK1EG&49JL&I+H=?4=
MB&0@"`(`@"`("V84_P"2=]-)\42`E:G>>\H!4[SWE`*G>>\H!4[SWE`*G>>\
MH!4[SWE`*G>>\H!4[SWE`*G>>\H!4[SWE`*G>>\H!4[SWE`8EW<O@:S@U<\G
M4UH*4[*ZUJ@(E]U</VRN`W-]P?BT0'14ZZG4U.NT[SZ4`J=Y[R@%3O/>4`J=
MY[R@%3O/>4!R":C4[1VG>@/'/4;'2=29UK&.D><QDO=:TO<?\Y-V`$J\M.EJ
M-?S5ZCYAF)RXA>6K_B2_:9TP8+*7%"VT=&TBO%,6Q"E:5H[W_@67=A':S-O"
MR+FR#2Z73VU[CXR'E3@,^/\`[%C\5?DBA<;)K[@:DGAO/S,[=NE"L0S[ME_P
MG)>GV'B]Y7PL[\=;M2_X=?\`5HRFY/[/GEMB[.]REEC+ITUK$ZX\/D+^YOK)
MS6&KHV6[WLX*@Z$EU*;%(CQ;,N2C"<E1OD5'VE5D^0_+^-:GDV;<G*,:TE)R
MCIT$):6%CCXN386=K90C7E6L$<#*[RV-K03Z3JMTI2EK)MLAVK%C'CN6(1A#
MFBDEW&4O)M"`(`@"`(`@"`B<C@<)EV\.4Q5C?:<(=<6['R-&GR90!*W9V.6R
M-VY#P2:(N1@X>6J9-J$^M:]NTU_DO)WI2\#W63\CB934M\/<>)MP2>V"[$CN
M$;@]JE0XA?CXJ279ZBBR?*?#+U79=RU)\SJNR5?64#)>2F<@#G8O*V&1:*EL
M5PV6PG<.P`GQ$!=ZW-"E1XC;?CBUWE%D>3\Z&N-<A<7,ZQ?M7>:_R?1?5>(!
M=?X+(,B!(Y\$?C(--2>;:.F:!36IHI4,FQ/PS5>SUE#D\(XIB??V;BCSI;R[
M8U*N202TU#AM::AP];30A;BNK33E!-`3KH*H*L]Q>77V5>G<UT_@NI.I^I<M
M=#-8JPRS<7AX;?'0V\=]!'<L@EO[@7MQ.]D<@:XM9$":T7-Y7'+T+L[-F$5N
MR:JZO8Z;-$?9O+W^,\#,P;'$.(Y-V7QK49[D$HI*232<GO-TK1T2/1W3ODCY
M5]+F.3&]&XR>ZB/$V_RXDS-[Q5!#A+D7SQL<TC3@8VBJ;O$<V]53N/=?(M%W
M'T+A_DSRSPVCQ\2V[B^U.MR7;*J[$;29''&UK(V,C8T!K6,:&,:T"@:UK0&M
M:!L`4.K])TJA&*48I**V):(LF&_03?2M_(6BYXO02\?2+ZR9:YS"'-<6N&PM
M)![PO!(,R/)7<>G-XQ^T'$?PM'?"@)BRR+[IYC>SA<&\7$UYH:4K[IJ1WH"3
MJ=Y[R@%3O/>4!P@"`(`@"`(`@"`(`@"`(!_UJ@-5YWS6Q&-GEM,7:R9B:)SF
M/N!*+>P#VC7ER\$DMP&NTJUH:>PE3+6%.:WIO=3[3GLOS#CV9.WCQ=R:=&ZT
MCZ'JWV&N\CYJ]4WE6VKK+%1G9X2W$LP&[GW9F[PT*5'#LKQ5;_+F*>[Y@XA<
M^[<;:Z%5]KJ4:_R^5RCN/(Y*]O7;KBXED9ZA&7<L#U!2(PA'PI(J;N1D7W6_
M.<WTM^K80MX/\I<!H_5.H`-Q!.@]`7LT-::%).T^LK!D(`@"`(`@"`(`@"`(
M`@"`(`@,FUO;RQ>)+*ZN+21IJ'VTTD#J[R8W-K[5B48R\23/<+ERT]ZU*47T
M-KU%UQ_F7U;84:^^CR,8%.#(0,F<=?\`'CY4]?6XJ/+$LRY*=1:6>.<2LO6:
MG'FDJ]ZHR]8OSAMI'LCS.)?;-.CKJPE,[&_VG6TP;)P[^%[CZ"H\\%K6VZ]9
M;8_F6$GNY5MQ7/%U[GKV,W#:7=M?VT-Y9SQW-K<,$D,T3N)CV'M':"#H0=0=
M#JH,DXMQEHT=+;N6[UM7;34K;V-&0L'L(`@"`MF&TLM?G2R$>D4CU'HJU`2B
M`(`@"`(`@"`(`@"`(`@(S);(?6_XFH"*0!`$`0'RY[6[3[.WN0'49Q\UI]J`
MZS,\]H'J']=4"VFG+YC&9#(.8QC'.OKISBQK6ESG3/)<XM`+B2=I4V+;BJ\Q
MS%V,8Y,Z)*LGZS%63`0$/U#_`+#F/]!-\06RU]Y#]8B9_P""O?RF>?U;'"A`
M$`0!`$`0!`$`0!`$!R"1L)'J*`B,C@,'EVEN4Q./OJZ\4]M&90=XG:&S-/J<
M%LA<N6_!)HB9&!A9?XFU;GUI5[=O>:^R?D[TI>\;K)^0Q,CAH+><7-N-OZF\
M$KZ&NM)`I4,^_'Q4EU_4463Y2X9>J[+N6I=#JNR57WGZ`=$XAV,Z+Z2L&3"<
M673>&M1(YO*=+R+"&/CX*O#>/AK2IHN7OS^)D7)TI6;?:Z^T^Y\&Q7B\(Q;"
M>]N8]N-=E:16I8'M<P\+A0]E=A]1V%:BQ>CH]I\H"Q8;]!-]*W\A:;GB]!*L
M>%]9+KP;P@)3$_O)^C=\80%D0!`$`0!`$`0!`$`0!`$!R`2"0#0:D]@&\G8`
M$!6;SK/H['73;&_ZMZ9LKU[N!MI=9W%PW!=LX3$^Z#FFIV&BVJQ>DMZ,)-=3
M(%WBO"[%SX5[)QX77R.Y!/L;)]LL5S:ON+:6*Y@?$\LGMI8YX7@QD@MFA<^-
MP(W%>$FI4>VI-4H7+;G!J4'%ZIIK9SH\2=I]9^-7[V_ES'RP+`"`X0$=/B[6
M8EW"Z)QJ28S0$G:2T@MU]%$!'2X205,,S7[@]I8::=H+@LC4CY<?=Q;87N`[
M6`/'XI)6`89!!H00=Q!!^%`<(`@"`(`@"`(`@"`(`@"`(`@/5'EM_P`-Q?TN
M0_CIU49?W\O1ZCO.`?VR'7+]J1>5&+DR8K.ZF_1P2$;RWA;^$ZC4!(Q82=WZ
M66./T"LA^``?"@)&+#VD="\R3'0T<>!NG86LH3WH"4:UK0&M`:T:!K0``-P`
MT"`Y0!`$`0!`$`0!`$`0!`$!&9+9#ZW_`!-0$4@"`(`@,%_RW??'XT!\H`AE
M;34>0_?[[_67/_NO4R/A74<S>_$SZWZS#7H\!`0_4/\`L.8_T$WQ!;+7WD/U
MB)G_`(*]_*9Y_5L<*$`0!`$`0!`$`0!`$`0!`$`0%ZP_F+U/AX;>T9<6][96
MS&Q0VU[;M?P0L;PLB9/$8IVM8T`"KC0*//%M3;>JD^8N<3CW$L2"M1E&=J*H
ME)5HER55'WDGG_M#8CIK'V=YU'@+\03Y"&S?/AIX;IT)DAN)3+X:[-L][!R=
M6B0G71>+?"KE^;C:DFTJZZ>HD9OGS&X=:A=XC8GN2GNUMM.FC=:2H^3G)KIW
MS[\INI2R.TZOLL=<OX0+//QS82?B<0`QLEZUEG(ZI^9*Y:KO#<ZSXK;:YX^\
MN[7N)_#_`#SY7XE2-K*A;NO[-U.V^V5(OT29OWINXM\A:2S8^XM[^%TK.&:Q
MGBO(G5C)%)+=\C#4;-=5678RC*DDTZ<NAV6'>LWK>_9G&<&]L6FNU5+7'C+Q
M^IC$8_:.#3^"*N^!:B69T>&;^MF)]$;0!^$ZOQ("2@L[>W-8V>^10O<2YU.T
M:F@K3L"`R4`0!`$`0!`$`0!`$!HKS5\^^G?*S)6^#NL/E<YFKBPCR3;:TDM[
M.SAMIY)8H#/?7',<7R/@=[L<3R`-2-%/Q.'W,N+N1DHP3IJ<CYA\XX/E^^L2
MY:N7<IP4J1I&*3JE63ZGHDSR[G_M<>8&0XX\#B>GNFXB2&RF";-7S14T/-O7
MQV8<6[?S%*JVM\'QX?>.4WV+NU[S@,S_`"1QF]58=NS8CST<Y=LJ+_::-ZA\
MR_,#JOF-S_6&>R$$E>*S\?+:V%'&I8+"R-M9\%=@+#13[6+CV?NX13ZJOM9R
M6;QWC/$:K,R;TX/[.]2/^F-(T]!1>!FONM]XU/NC4G:3IJ2I!441.8;J;J/I
MISYNGL]F,))PN<3C,C=6;'D,=3F10RMAE'H<TA:[EJW=5+D5+K1*Q\_.P$Y8
M5Z[:E3[$G'M2='Z4:VP?VB_,O$B..\O,;U#`PT<W,6#!<O:'$FM]8/LYBXC2
MK@]2[G#L:3T3B^A^QU(.-YRXUC/=N2A>BOSUKVQH_6;LZ5^T[B,M>8_&]0=-
MWN*N;ZYM[,7N-N69"Q;/<RL@A<^"9MO>1Q&1X#J<PM&NJ@WN&3A%SMR325:/
M1_0=+@>>,?(NPLY5F5N<I)5BU*-7HM'1T[3U)PFI%*EIH::T(]2JCN^@X((V
M@CUZ(-FT(`@"`ZY(HI122-CQ_::#W$BH0$?)B+.2I:UT1_9NT_!<'!`8$N#>
M*F&9KAV-D:6GO;Q!9&I'28^\CK6!Y`[64>-E3\DDK`,0@@T((.XC7N0'"`(`
M@"`(`@"`(#*CLKJ459!(0=CBWA;WN+11`2$>$G=0RR1QCM#:O<.ZC?A0:GK?
MRPP]HWHS%&0RS.YN0VNX&_O]QV,`/9O51F*F1+T>H[S@/]MAUR_:D;*CMK>'
M]%#'&=[6CBUV^\:N^%1BY.Y`$`0!`$`0!`$`0!`$`0!`$`0!`=,T#)VAKZBA
MJ"TT(W[010H#`?CC^KD!]#Q3X17XD!BOM+AFV,N&]GO?`-4!CD$&A!!W$4*`
MX0&"_P"6[[YWQE`?*`(96TU'D/W^^_UER?9S7J9'PKJ.9O?B)ODJ_60%WFL3
M8U%WD;2%PVQF4/E]7*CXY*Z;EMC:N3UBFR'=S,6SI=N13YJU?8BM7?7V)A);
M:P7=Z1\[A;;1$_?2DR$?W%NCB7'XJ(K;O'<:.EJ,IOL7?KW%/RW6>1R=O-9L
MAM[.VG:8Y1'QRS21DZL,LAX6AU->%H/I4FWC0@U*K;1597%LC)@[2486Y;>5
MM<U?J*>I!5!`$`0!`$`0!`$`0!`$`0!`$`0&G_.O_BUC_P"<MOX._5AP[[]_
MJG*^;_[?;_G?N2/,5*Z'4'L5P?-3]1/L"@-Z&\P0T`#^;\?H!0?[''N7(^8_
MQ%O^7^\S]`?X=TX1FT_]U#_MGO%<Z?80@"`(`@"`(`@"`(`@"`(#\WOM;?\`
M]0LO_P`AA_XS*KIN#_A'^N_4CX9_D;_]#'_XUOUS/+ZM3@@@.ZWMKF[>([2W
MGNI":<%O#).ZIV5$;7$>U&TO%H>[=NY=>[:C*3Z$WZBUV?0/4]\PDV+;%CF.
MH_(2MM]"TBO*;S)]-W"%HEDV8\M>HL[7`N)7XOW-R--LG3NU?<:VQ?D(P!KL
MWU"\NK5T&)M0UORMGBKMSB:C]D%(EQ/>UA#M^HB8_DU/WLN_KS07ME]!M/I?
MRLZ(Q&2Q<C,1X^XBR%E(RYRD\MX\/9=1.8\1$LM6N:X5%(]"H5_,R)VY+>HJ
M/9H=#@>7>$XM^W*-K?N*Y'63<OM+DV=Q[VX&,+@QC&"NQK6M&AW`!<^VVZL^
MM[L5HDDCY>QD@H]C'C91[&N'<X$)5K8S$HQDJ22:Z2-FPV.FK^8Y3C\Z%SH_
MQ:EGP+9&]..UU(MS!QKGV=U]&GU$7+TV-3!=4W-F97\=A_[5M61^<B)/A>G\
M*>O2OH(J;"Y&']3S6_=0N#^]ONO'<MBNVY<I$N8.3;^SO+HU^LC7QR1'AD8^
M-VZ1KF'N<`MB:>PBM2BZ233Z3Y0P$`0'7)%%**21L>/[303["14("/EQ%I)J
MT/B/[-VGX+@X=U%D$?)A)!^AF:[T2`L/>.(?$@(^7'WD5>*!S@/G1_G!^+4K
M`,?E2_X4GX#OZD!W1V5W+3@@DH>TMX6][J!9%20BPL[OTLC(Q78VKS3N:/A0
M:DA%AK5GRS)-]\>`=S*'X4!GQ6T$/Z**-GI#17\(U<@H=ZP`@/4WEI_PW%_2
M9#^/N%4YGW[]'J.\X#_;8=<OVF7M12Y"`(`@"`(`@"`(`@"`(`@"`(`@"`(`
M@"`^7,8\4<UKA_:`/QH#'=8V\AH&EA/:PZ;#\TU"`K\UH1)(&O!H]X]X4V.(
MVBJ`ZQ:O.US1ZJD_T(#N9:Q@CB+G:CMH/@U0'A[K+)Y&7J3J"VDOKIUO!F<G
M#%!SGMB9&R\F8U@8PM:0UK0-:E=!8MVU;BTE5Q7J/DG$\G(N9U^$YR<%=FDJ
MZ44GS%0WG?J?3ZU(*VB6P(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`T_P"=?_%K
M'_SEM_!WZL.'??O]4Y7S?_;[?\[]R1YB5P?-3]1?L#@_R-Y@FAI_-^/%::5&
M#BJ*[Q5<CYB_$6_Y?[S/T!_AU/\`I&:^3YJ'_;1[P7.GV$(`@"`(`@"`(`@"
M`(`@."0-I`]9`^-`:+\TO)+H_P`T+Z/,Y')YC$YVWQ[,=#>XUT%Q;/MX))9;
M=ES8749CD,3YGZQR1.(=J=`IV+GWL6.Y%)VVZT?/UG*<?\H</\P7EE7IW+66
MH*.]&C5%5JL7S5>QH\ZW'V2\C;S/D@ZIM\K;-<2R!MI]57;V4J`^2>6]M@^H
M[#16/]9A+1P<7SUJ<9/_`!G?MO>CDQN0YMW<E3K;DJF$_P`F&].4?=]*7D_`
M?WJY#\I`2!MK;NDM0/6T!>_GOBZ*:UY-AY7E2U@>]=QINGVI5FNZJ[CNBAAM
M6<J"&*U8W3E11L@:*::L8U@'M"Q7>VNIOC"U;6[",8I<B5.XE['"Y?*'AQV,
MOKPD.HZ"VE='H#ME+1$T>MP7B4X1\32)5K'R,A-6(3GIR)T[=A7K+RVZBNB#
M<BSQT9)J;B<32@?0VPDU];@LO)MQ5%5LT6N"YMRF_NP72ZOL1=<5Y9XZRFAN
M;W(75]+!)',V.)C+2WXXW![>+6:9[0]H^<VO:M$\J4E2*2+*QP.S;DIW9RE)
M-.BT55VLV6=37>HI>!`$`0!`?+V,D'#(QDC=SVM>.YP(1-K88E&,U2:373J1
MLV&QTU3R.43K6!SH_P`4$L^!;5>N+ET(L\'%G]G=?1I]1%R]-C4V]T1N;,RO
MX\=/R5L61SHASX7_`-*?:O:OH(N7"Y&*IY`E`[87M?\`BU#_`(%M5VV^4BSP
M<J'V:KH=2,>Q\9X9&/81V/:YA[G`+8FGL(C3BZ233Z=#Y0P$`0'-3O/>4!P@
M"`(`@"`(#U-Y:?\`#<7])D/X^X53F??OT>H[S@/]MAUR_:9>U%+D(`@"`(`@
M"`(`@"`(`@"`(`@"`(`@"`(`@/IGRA[?B*`@9OTLOTC_`,HH#K0!`:OZM\J.
MGNJ;F;),DN,/E9Z.GNK-K)8+IX`',N;.0M:Z4@:O8YA=VU.JEV,RY96YXH?E
MRG/\2\N87$+COIRM9#VN.J;YVGR]*I7E-093R-ZIM*NQ=[C,Q&!HSF/Q]R=P
MX+GC@)/TJG0XA9?C3B^U'-9'E/B-K6Q*W=CUN+['5=YKG*](=480GZTP.3M6
M`G\_X9\]L::$BYMN=!P^MP4JW?M7/!),I,CAV?B?B+-R*YZ57:JKO*Y4'MV;
M?1ZUM(50@"`(`@"`(`@"`(`@"`(#Z:USW!C&N>\[&,:Y[S7<UH+BC:6KV&4F
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M]KYB5Z2^P0P/M[CKGS`$L0+'SXSI+&N87B@+H1F<JXEOO5'&VT.FHHLWO,>C
M6/;UYY/V+Z37PW_#M)1GQ?,JN6%F-/1OS]:@>[>BNB.F/+SIZSZ7Z1Q<6*P]
MF7O;$'/FN+FXE-9[V_NY2Z>\O)W:ND>2=`!1H`'.Y&1=RKKO7G6X_P`M%R'U
M_A7">'\%PH\/X;;5O%CR;6V]7*4GK*3Y6^K9H6M:2Q"`(`@"`(`@"`(#JDFC
MB`XSJ=C1JX[=:=@T[4!B.OON(_:X_P!`_K0&.ZZF=\[A&YHX?AVH#H+B[5Q)
M.\DGXT!P@"`Y!(V$CU(#`FQF,N91/<8W'SSBE)IK*VEETV?G'Q.=IV:KTIS2
MHFZ=9IECX\Y;\[<'/G<4WZC,=I&YHH&AC@&@4:`&F@#10`!(^)&W9&BV4-)'
M:?6I9S+VLX63`0!`$`0!`$`0!`$!\O8R1O#(ULC?N7M#V]S@0LIM;#$DI*DD
MFNG4C9L-CIOU'*-#[T#C'J>WAU8>Y;%>N+EKUD2>!BSUW=U]&GU$7-TWM-O=
M>IL[*_CQT_)6U9"^TB)/A;_Y4^U?1]!!7=A<V)`G91KC1DC#Q1O.X.TH?00"
MMT9QGX60+V/=QW_$6G/R,PUZ-`0!`$!B7M_8XV(S9&]M+"(4K)>W,-LS4T&L
MSV5J=R]1C*6D4V^@UW+UJRMZ]*,(]+2]8LK^QR40GQU[:7\)K26RN8;IFFW6
M%[Z42491=))I])FW=M7EO691G'H:?J,M>3V>IO+3_AF+^ER'\?<*IS/Q#]'J
M.\X#_;8=<OVI%[44N0@"`(`@"`(`@"`(`@"`(`@"`(`@"`(!MT&J`C<GFL/A
M8S-F,KCL5$-./(7D%K4TK1K97M>\T[`"5ZA"=QTA%M]"-&1E8V)'>RKD+<?T
MI)>LUED?/+H*RDY.-N<CU+><7"VUP..N+@/<0:`7%P+>`@G2K2[53(\/R'K.
MD(\\F4-[S9P>$MS'=S(N<UN+?>Z+LJ0]]YC9%[&308)^-%Q&V<#)\U\\9E`=
MP.8QL$8<VM"*G5>8XT:T<D^H]3XW?<%*-EV]Y)^_6JKR4TU15+KJ[J*[=5V3
MFA&ON6C66S`#]&T//M)6U6;2Y$0+G$LV[MN-+]'3U&%'U!G8SQ,S&1!K7WKJ
M5X]K9'.:>Y>OAVZ4W4:UFYB=5=GVE@L^O\];T;.;6^8*5Y\/*E('[6W,>OI+
M2M;Q[;V51+M<8R[>D]V:Z51]J^@M5GYCXZ3A;?6-U:N-`Y\#F7,(/:>$\J4-
M]A*TO&DO"TRPM\;LRTNPE'JHU[&6JSZEP5]06V4MN)U!RIGFUD).@:67`CJ:
M[JK5*U<CM3+"UGXEW2%R-7R/1]C.C*=(=+9L.=D\!B[MTE:W(MF0W!)%.(7=
MMRIBZG;Q%(WKT/!)H\9'#>'Y>M^S;E)\M*/M5'WFN,GY&]+W7$[&7V5Q,AKP
MM,D>0MP?2RX:R<-_]52X<0O+QI2784>1Y2P+FN/.Y;?-7>7?KWFM\IY'=56G
M$_&W>+S#!L8V5]A<D;^7=`P'U"6JE0XA9EXTXOM*3(\J<1M:V)6[JZ'NOLEI
MWFN<ITEU/A*NRF!REI&#0SNM7RVW;KXFWYL%#3[I2H7[-SP23929'#L_%_$6
M;D8\]*KM55WE>!!V&O\`7N]:W$*J"P`@"`(`@)G%]/Y?-!SL=9NFB8[@?</>
MR&W:^E>'FR.:'.IV-J0M=R];M>-DO&P<K+J[$*P7+HEVLN]EY97C^%V0R4$`
M^=':1.N)/4))>5&.YRBRSHKP*O66MKR_=EK?N1BN:*J^UT1;;#R\Z?@+0Z"Z
MR4H[+B5SVD^F"W;$TCT&JCSS+KV-)%M9X'A1:K&5R72].Q41?<?TQ);-#++&
MV]@S0<0CAMJC94A@$KM-XJHLKKEK.3;+FQPYVU2U;C"/0DOK)Z'IP[;FZ]D#
M*GTU?(?^U:_B<R)L<#\^782D.&Q\-*PF9P-:SN,FO9[H#6:>I>7-OH)$,2Q#
MDKUDDQC(F\,;&1M^Y8T,'<T`+S6NTD**BJ122.UFWV?TA#)D,DDC-6/>S[UQ
M'Q(#,9DKEORG-D^_:*][>'5`9C,JPTYD3FFE*L(</70\)^-`9T-Q#/7E/#B!
M4M-0X"M*\)H2*H#O0!`$`0!`$`0$/=5Y[Z[Q3U<(0&.@"`(`@"`(`@'_`%KL
M]M=$!KC(6O3DLLC[7)>%?Q.XHO#7,]OQUUY;F15:TG<7#<I,7<2]Y512W;>$
MW6W.CYJ-KU%=FBCC-([F&X&^)MPWVTG@BHMFTARBD]&FO3[4CH63R$`0!`$`
M0!`$`0!`$`0$7FO]LGV?*@I6G^,S97MI5;;/WBKL(?$*?*2Y]*==2A*:<\$`
M0'GSS*/FT[,7HZ?&69TVV.W%H<+X3GO)MHS=&3PI?E*BX+Q[P:*`4TH398OR
M>XOB[OQ>GZ]#D^+_`->^8E\K\3Y2BIN4KLUK3WMM=OH/,M_]8>(/UKX[Q=37
MZS\3XFM=:^+_`#NU6L=VGN4IT?4<9=^)O_Q][XGZ5:]YW8F.^ENV-QD]S;W-
M122R&0,PU%*#&0SW.W^S18FXI>^DUTT]I[L*Z[B5AR4_T:U_VZGL?RAQ?58S
MV-=UYU/F']*$7!OXKG&7(N`!:R.M6Q7%[:#+CBN0P$QQ.T)V;529T[7PY?+P
MC\?DU^AT/H'EZSG?-P_JUVY_3Z/>K%UV.FK6_MIL3/T=POU5]56/U'R/JKD#
MP7AZ\OE<1XC[U'\PR5X^+WN.M=:KE[F_OOXE=^NM3[3B_+_+P^5I\O32FS\N
M>NM247@D!`$`0!`$`0!`$`0!`$`0!`$`0!`1N1OKJRB+[7#9',24J(;";$P&
MOW+I,ID\>UM?1Q+W",9/WI**Z:^Q,T7KMRU&MNU.X^:+@OVYQ-79GJCSAEYD
M?3WEG9V;3Q-CNLQU+@KR85T:_P`+:Y6U@:X;:&1X4N%G!6MV\WU1:]E3G\G/
M\S2K'#P(Q7(YW;<GUT4TO15FENJG_:+EAEDRD6=M[,AQDAZ;^KS"UG#[P<>G
MYKFYX`S[IY4^S_2TZ0W7+]*O[VARW$7YWE%N^KT;7*K6[3_PVWWE&Z-_E'BO
M#UP:YOQ@%LW._6%?#<AE3+SP(>(S<5>::[-%MR?CZ?*_=T^S3:0>"_T>DWQJ
MGSF_I\3>V46VNE:UVF_L7]4^'9]3?5WAN$</U;X;E\/I\-IWJHG\3>_B5WND
M[[&^4W%\G\+X=/L;M*>@M+"TP-YH:UG``>:6%A%!J>+W:'TKR3G3=][P])4\
MO_+9@N.'P@O.5)R3;<53-PG@#N0#%\K[K1;8?$Z:?ESE9E?T_<E3<^-32G/Z
M-"AJ04@0!`<&E-:4].Q!IRD[A_YCXA]2G*C9^Z\_DTK\ZH,%*[UJG\+[>[4E
MXWSM?_+?$]%:?0;%LKKS$MPWQ&,MK^.@%+B;'P3=FI?#=QN!];2H\EC/8VGZ
M?H+NW<XW#QVXS72XI]S]A:K/(Y66C;[I^ZM'=KX;[&747<;N&4=Q6J48+PR3
M]#^@L+5[(EI=LRB^B46O6B<;Q%I(#@*>\#L`IJ'4);0=O8M9*Y.@UKU4?*RK
MOYG'31G+75+>7]8@5%?]L/C>*N^I4JS\W_RM^G=WZ%#Q'_Z]_P"O^!O_`.[_
M`&>\:7RF'\E[OB=BNK<IB)-:,=C,QD+:O91ESC&7'"/1*5/A<SX^*$9+K2]I
MS&1B^5KNN/DW+4OU)R7?&O>:XRF)Q-F7.QO56,R\8KPM;C\]87+@-@,=UC/#
MAQ^EIZ5+A.Y+QP<?2G[?84>1C8]I_P`#(MW8_JW(OL<*=Y7UL(80'?;PLFD#
M)+JWM&G;-<BZ=$WUBTMKJ8^QBQ)T6QOL]K1[A%2E1RC%<[K3N3?<>C^@L?B(
M.GK=GU_!?1^)NG<ZRL<C''QN>"Z,>/M+>:K-A/+`/8J?+E)WF]UI]:]C.[X'
M8Q88"B[RFMZ6L8RIMV>\D^XV'`WIUI`XVR.^ZN><!W/9''\"B_Q"_MK`6QUZ
MZ^TL4/(X!X?D\'9R>7P^WEZ;%K=>7:3H[M/<IN]!VK!Z"`(`@/MFW;V;/:/8
7@.U`$`0$CC?WD?1/_*"`GT`0!`$!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g18512tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18512tx_pg03a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C0+&`P$1``(1`0,1`?_$`.```0`!!`,!`0``````
M```````%`08'"`(#!`D*`0$``04!`0$!````````````!0$"`P0&!P@)"A``
M`0,#`@,"!@@/#00(!P$``0(#!``%!A$'(3$2$PA!46%Q(A2!D;$R4Y34%?#!
MT4)2LB,S<[-4E=4V":%B<B0T=+0U5746=M9#9+66X6.3TT0E%S?Q@I*BPF56
M&1$``@$#`00%!P@(!`4#!0````$"$0,$!2$Q41)!87$3!H&1T2(R(P>AL<%2
M<K(S%$*2TG,T%34(\.%B=(+"4],6DR08HD.S)1?_V@`,`P$``A$#$0`_`/W%
M$G4\3S/A/CH"FI\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\
M9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@/+.
M),*5J3]Y5[HH"R*=72"Q<DW!L>/A<=M8NER&J?5(KB>S94"/Y5)!4AK16FJ4
M]2_(*V+6-<N;7ZL>+(C.UG$PV[<7WE_@MWE9@'(<QO>2.'UZ1V<1*^IFWQ]6
MHK1'O2I(]-]P?9+)/BTJ3M68652&\Y#-U'*SI/OG2W]5;E]+\K+8ZC]!5]6L
MIH#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U
M:`E+5?+I99(EVV8[&>X!72=6W4@Z]#S1!;=1KX"#Y-*LN6XW(\LMQL8^5D8E
MSO<>3C/_`!T;C.F.;IVZ?V<6^-IMDHZ($M!)@.JY`KZM5Q"H_9%2>/,5'7,.
M4=MO;$ZO"\06+S[O,7=W/K?HM_1\IE5"T.(2XVM#K:TA2'&U!;:TGDI"TDI4
MDCPBM-IIT>\Z%.+7-%IQ?2MS.5"HH!0"@%`*`4`H!0%UV0GU-?X97N-_5H"6
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT!Q4X$#J6OI3XR3[0',D^*@(MZXJ/HLZ
MI!YJ(]/SIUY:^7C0$<5*))*E$DDDDDDZG7B:`IJ?&?;-`-3XS[9H!J?&?;-`
M-3XS[9H!J?&?;-"JWFG>4_K+D!/]L7#^DN?4J<M?A1^RCS'4')ZC>BG3WDOO
M$#P\OM_]%9#4Y9_6^0QYE^V..YAUOK:7;;ROWET@)`==5]:F9'X-S$C3GZ+F
MG)0K;Q\R[CO8^:WP?T,@-6\-8&JMSDN[S7NG'>_M+=)?+UF'QW?,HM\LN9%*
M:BV3K"6)L'K7(F!0)2GL70/F]9_ZW4Z^]!YUOO5;4XTM)NYP9R*\":CCW7+-
MDHX==DHU<I+K7Z/E,L63'K1CL7U2TPVXR5=)>>)+DF2M(.BY#ZR5N*U/+@D>
M`"M*Y<N79<TW4ZG#P,73[7=8L%&/2^E]KZ2:JPVQ0"@%`*`4`H!0%G9-@MAR
MA)<E,JB7#IT1<X>B).H'HA]/WN4@<M%#73D16:UD7;.Q;8<")U/1L+4TYW8\
MN1T3CL?EXKJ\QKKD^W^18R5OK;-QM@)*;C#0M24)_P![8U+D8^4ZH_?5+V<J
MU>V5I<X,X#4]"SM.DYR7>8]?;CM_66]=NXL3M%>`ZCP'CQ_=K9(0IVJ_'[OU
M:`=JOQ^[]6@':K\?N_5H"?QO&LDS"Y-VC&K3-O$]9&K41I2D,))T[67(44QX
MC">96XI(TK%>OVL>'/>DHKK-_3],U#5<A8FG69WK[Z(K8EQDW2,5UMHW@VX[
MJ=KMACW7<68F^3D]+B<=@NN(LT=0T(1/E>@_<BGPH2&VM>'I"N<R];G-.WBK
MEC]9[_)P/9O#WPOQ\?ER=?FKMU;>ZC^&OM2WS[$DNMFW4.)%@16(4*.Q$B16
MD,QHT9I####*!HAIIIL)0A"1R`%0,FY2<I-N3WM[V>JV\>U9MQM68QA:BJ))
M)))<$BZK.?N#_P"&3]H:P7/:\AO8RI%]I--NN-+"VUJ0H>%)TU'B/@(-6&R3
ML:[A6B9&J%<!VB2>@^521[TZ^Q0$N%]0!2OJ2>(4E6H.OB-`5U/C/MF@&I\9
M]LT!4$Z'B>7C/C%`4/,^<^[0%*`4`H!0"@%`*`4`H!0"@%`*`4!:66Y79,;M
MTLW&4/62PKLH#'2[,>/`C1K4=F@_9+*4UEMV+MSV5ZO'H-',U'$PHUNR]>FR
M*VM^@U0R;<>]7P+C13\TVY1*2Q&=5ZR\C7@),E)2O0CFE'2GSU(VL6%O;+;(
MY#-UO*RTX0K;LOH3VM=;^@QV3KS^CQD^$DUM$0W4I0H*`4`H!0"@%`*`4`H!
M0%U8]F-[QQQ(@R.TB$_=($DJ<B+'(E*=0IA>GUR"D^/6L%W'MW526PW\/4<K
M!E6S+W;WQ>U?Y>0SYCFX-DR#LXZUBV7)6B?5)3B>S>5IRB2?1;=.OUIZ5Z>`
MU'7<:=O=MCU(Z_!UK%S/4F^2]P>Y]C+[K7)<4`H!0"@%`*`4!=5D_D;GX9?V
MK5`2U`*`4`H!0"@%`*`4`H!0"@(VY'T61^^43Q/$@#0^P#0$30"@%`*`4`H!
M0JMYI[E/ZRY!_?$_^DNU.6?PH_91YCG_`-2O/HYY?>.NW6*;<-%A/81R?OSO
M#J'_`%:."ED^`\!Y:3NQCNVC'Q;]_P!:G+;X^A%]V^S0;:$J;0'7]"%2'=%.
MZ^'IT'2V#Y/;K7E.4MY,8^):L[4JRXO>=61MH=L5U2XD*"8;SH!&NBVD]HA0
M\1"A5;5>\36],IJ$8RPKO,JTMM^;::^U*G""@%`*`4`H!0"@%`*`<]00""""
M"`001H00=00:#?L,793M99+[VDJV]-DN*B5=3#85`D.'77MXB=.R)/US>GE!
MK;LYMVUZLO6A\OG.:U+PUA9C[W'2LY#K[*]5OKCT=J->,@Q2^8P]V5VAK;;4
MHAF8UJ["D#70%J0D=/41]:KI6/"*E;5^U>5;;J^&YG!9VFYNG3Y,J%(O=);8
MOR\>HMRLQI--;RA.@)\0)H49]=]F[%:;%MKA[=J@QX9N./VNY7!UEI"7ITZ;
M%:DR)4MX)#C[BG'3IU'1*=`-`*X//N3NYEQW&W2;2X))M?0?57A+!Q,/P[B1
MQH1@[EB$YM+;*4HIN4GO;=>G<E1&3JU#IA0%Q6;[P]^%3]I6&Y[7D-JQ[+[2
M7JPSB@)6TN+$@MA1Z%-J)3KP)!!!T\!H"XZ`4!4<CYOIB@!YGSGW:`I0"@%`
M*`4`H!0"@%`*`4`H"/N=VMMEC*EW28S#8`5TEQ8ZW5`>\8:&KCR_(D&KX0G<
M=(*IAOY%C&CSY$E&/ROL728-R7=>;,[2)CS2K?&/4DW!X(5.<2=1JRC13<4>
M(GJ7YC4A:PXQ]:XZOJW'*9WB"Y=3MX:Y(/8V_:\G`PU<GG7V);S[KCSSB5*<
M==67'%J)!*EK62I1]FMU))4CL1SC<I2<Y-N3WMNOSEC'F?.?=H4*4`H!0"@%
M`*`4`H!0"@%`*`4!77EY#J/&#IIJ#SIOW@R'C6X]ZL0;C2E&ZVX$)]7D.$2&
M$#0?Q:20I8``X)7U)\U:UW%MW-L?5D3&#K65ATA<K=LKH;VI?Z7Z>PSW8<JL
MF2-`VZ2/60D%V"^4M2VO&>R*CVJ/WR"4U&W+%RU[:V'7X>H8V:JV9>M]5[&B
MXO\`X?1XZQ;]IO"@%`*`4`H"ZK)_(W/PR_M6J`EJ`4`H!0"@%`*`4`H!0"@%
M`1ERY,^=?N)H"*H!0"@%`*`4!Q4M*.9]CPT!@"=8X2+[=ISJ?67G[G+>2ET`
MM-=;ZE)"6^*5*3XSKQ\`J2C<;MQCT4./N8EK\Y=N2VR<Y/;T5?\`C:>LG7P`
M:<.`TH9DDMQ2A4B;_P#U'=O[OE?BC5]KVUY/G-//_@KW[I_,S7JI4X,4`H!0
M"@%`*`4`H!0"@%`=3[#$IAR-*8:DQG04NL2&TNLN)(T(6VL%)%$VG5-U+;EN
M%V#MW8J5M[TTFC"N4;/19!<EXP\F&Z=5FU25J,1:N93%DGK7&//1*^I/E`J0
ML9\HKEOJJXK><=J/A*U.MW3&H3=?4E7E\DN@P%=+5<;/)<A72&_!DI!^YOH*
M>M/'1;2_>/-GP*22#4G"<+BYH.J.(R<>_B7'8R8N%U=#^CBNM'U^VS_]N<#_
M`,HV#_AL>N$R_P"+O?O)?>9]7>&_Z#A?[2U]R)>]:Q."@+BLWWA[\*G[2L-S
MVO(;5CV7VDO5AG%`25J_E8_!K^E0%S4`H"HY'S?3%`#S/G/NT!2@%`*`4`H!
M0"@%`*`4`H#%N;[B#'WU6FTMM2;HE/\`&GW=5L0"M(4ELM@CMI720="0E.O'
M4\*W,;%5U<]QT@]W^9`:IK?Y27Y?%2E?6]O<J_.S7VX7.X7:0J7<Y;TV0O75
M;RRH)!.O2TC@VT@>!*0`*DXQC!4BJ(XZ]>NY%QW+TG*?6>*JF(\L[^22"?`V
M?I4!91YGSF@*4`H!0"@%`*`4`H!0"@%`*`4`H!0':T^\PXAUAUQEULA3;K2U
M-N-J')2%H(4DCR&C2:H]Q=&3C)2BVI+<UO,R8ENA*0['MV1J$AA92TBZA.DA
MA1(2A4P)T0\SJ>*P`I(XG6M"_BK;.WLZCI=.U^XI1L9OK1>SFZ5PKQ7%[S/'
M`\4D%)XI(.H(/$$'P@BH[MWG7=FX4`H!0"@+JLG\D<_#*^U;/N"@):@%`*`4
M`H!0"@%`*`4`H!0$9<N3/G7[B:`BJ`4`H!0%"0.)X4!T+?YA'#P:\?<-`=!)
M)U)U/EH#$MS_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.[?W?
M*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`C+O9[
M7?8BX5VA,36%@Z!Y/IM*(TZV'4Z.L.`<BD@U="4K<N:VVF:V7AXV;:=G)A&<
M*;*]'6GO3-P\1M+=NQ#%H40N&/$Q^U1V0XKK=#;,-EMOJ5H.L]*>)X&H&_)R
MOSE+VG)M_.>LZ5CQQM*QK-GV86(17&BBOH)KEP/,5B)"O04H"XK-]X>_"I^T
MK#<]KR&U8]E]I+U89Q0$E:OY6/P:_I4!<U`*`J.1\WTQ0`\SYS[M`4H!0"@%
M`*`4`H!0"@%`<5J*$.+'$H;<6`>1*$%0U]JJK>6R;46UO29I-)D.RY,B6^HK
M?DO.ONK))*ENK*U$D\3Q5PUJ>244HQW(\OG)W)RN2VRDVWY6=-5+!0'4\@.-
M.-JY+0I/M@Z>?C0%D.M*9<6VL:*2H@CW#R`T(-`==`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!2E=X-L<!FO3\1M#SZBMQMMV(5DDJ4F(^XPV5$\SV:0/8J'R8J-
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MM'-'LH!0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!Y7EDJZ>`"0!P\
M/(ZGRT!TT`H#$US_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.
M[?W?*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`4
M#-Q<7=;>QG'UM+2XCYIA-]22".MMA"'$ZCZY"TD$>`U!7?QI]IZWI4HST^S*
M+3CW<?D23^5'OEH`*71PZE=*@.7`:Z^SI6,V+RI1QV'DH6%Q6;[P]^%3]I6&
MY[7D-JQ[+[27JPSB@).T@F5KIP#:M3QX:Z`>V10%RT`H"HY'S?3%`#S/G/NT
M!2@%`*`4`H!0"@%`*`4!UO?>7_P#WXI=56]=I;/V)?9?S&D53YY8*`4`H#QR
MH3$H?=!HO0A+@X+3QU`Y:*2/$:`MR5;GX^I">T;UXN('+^$D:E/[HH"/*2GG
MIQH"E`*`4`H!0"@%`*`4`H!0"@%`*`4!M-MI^IMM_#S_`.F/5$YGX\O)\QW^
MA_TNWVR^\R^ZU26/CI^VT[I5Y[RW=*<S;#!=)N?=VV?=]SK7C<%<EYC*<1EV
M]B#N#;T6QHJ1*OEKL<)%QA+2@N],1]E/!\UR_BS399VG=_:J[UA\R2Z8O9+9
MQIM73P/J+^T[XD8O@;XC/1M4[N&DZ["&+*[)*MJ\I.6.^?HA.;=J:;I6<)/V
M#\.T-F1<)$.';HLFX3KA(C0[?!A1W)$N?,F/(8A0X;"$J7(DS'W4H;0D$K6H
M`<Z\GKS>K%-M[$N)^LMQPLPE=O24+4(N4I2=%%159-M[DDFV^A(_5WC7>%RC
M]D)L=LAW4L(L>)Y[OC-Q^7O'WCDYI-O=QL^`9IN2B%<;1M]C\*TW2`W`FV2R
ML-B8->A:@E[IZI"E5]5_#7X<PRM![[4YWK<7+9RM*LOTMZ?JK9'9ODFS^9W^
M_?\`O8R+7QNO8_@;$P<NW:M1MRE>4Z1L0JL:O=SBW=O+GR)<S?):G9A2ANKW
M"?VL64]Y+>]K9G>G%L!PQ[++/).W=VQ/YYBHG99;B9;V.707JZ7%+CMWM:7%
M0BWT$OL]F>HN)TZ#Q3X$L:-ISU'3KEVY&$UWBG1M0>Q27*EN>_8]AX1\#?[I
M=3^(GC1>$/&&+@X=S*LO\K.QWB4K\?6=F:N3E5W(*7=TH^>/+MYE3[BD:5YH
MMJ/M);54I0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!XG/?J\]`<*`
M4!B:Y_UC/_GDC\8JM^'LKL.:O_Q,^U_.>&KS&*`B;_\`U'=O[OE?BC5]KVUY
M/G-//_@KW[I_,S7JI4X,4`H!0"@%`*`4`H!0"@%`*`4`H"XL?RJ]XT]UVZ42
MPI?6[!?U=AO:\^MDD="R/KD%*O+6&[8MW5M6TD,'4\S3I<V/+U'OB]L7Y./6
MJ-&;+=NIC,]F+'N\EC'[A*D,QF6[@^VW#E2G$N%#,28YT-]HYV9Z4+Z5$C0:
MU'3P[T&^1.44JNG0CL<;Q-I^1&,<J<;-Z3HE)TC)NM%%OI=.DOOR^`\0?&"`
M01Y"#6L3R:>U5+BLWWA[\*G[2L%SVO(;=CV7VDP`5'1())Y``DGS`:FK#.2\
M:TN*/7)/9H^#&A<//F>2/W30$XTRTRGH:0$)YD#PG3F22230'90"@*CD?-],
M4`/,^<^[0%*`4`H!0"@%`*`4!$WN_67&K<]=K_=(5GMK`)<ESWT,-Z@:]FT%
M'M'WE`<$-A2SX!5]NW.[+DMIN74:V7F8F!8>3FW(6K"WN3IYN+ZEM-4+[WP;
M'$O'JU@Q29>;*V[T/W.7.%LER4]72MR!;_5Y&C9'%/;*0H^$)J5AHUR4:SGR
MSX+Z6>=9?Q+Q+63R8>-*[BI[92ERM_9C1^2K5>E(V`PK=##-QK:Z_C5U;<F)
MBO+E66641KS"^Y*ZNVA*62ZTD_[1HN-GQUH7L6]C2]XO5KOZ&=EI7B#2]<QW
M/!N+O>5UMRI&<=G3%[^U5J:QU+HX84`H!0"@%`14NULO]2T?<G#J24^\/+WR
M.7'3F.-`6[(AOQ3HZ@Z:Z!8!*%>+17+CXCH:`\U`*`4`H!0"@%`*`4`H!0"@
M%`*`VFVT_4VV_AY_],>J)S/QY>3YCO\`0_Z7;[9?>9D%EAZ0L-LMJ6K4`@#@
MG7PJ)X)'#PUJDL8H[R&\.,=V/8W/]ZLQ+4UK%+0L66QEU+/^(\LNBO4,9QME
M1T+J[I='D!W3@F.EU?%*#4IHNEW=:U.UIMG?<EM?1&*VRD^Q;N+:1Q'Q'\<Z
M?\-_!>=XPU%UCBV_=PK1W;\_5LVH[:UE-JK6U14I=!^8%G]KSWN8[K4ABU=W
MUAUEU$AE+.QV+-!I;3@<0AE]"DR&PV4@)6E0<&FH/57LW_\`-?"RI2%ZJ6]3
M2=>-%$_.-_WJ?'R5>?/PW&6].Q)II[T_>[5T/J-;.^`%97N'$[QL.XS+EB/>
M=B2]S+9,N<U4V9C^8-OMVK<G;2XS'"-9>`9.RIB(@Z*59'H#@&BQ70>'VK&+
M_)Y14;^$U;:2HI0=96YI<)1]KH4U)=!X]\5ZZGK\?B!9G.[I?B.,LN$I2YG:
MOI\F7B2EL];%O)Q@J+_V\K$J)2+;[K&,L7K=.'GETO-PQ[`]BXJ-Z=P\GLLO
MU2ZVVQX5<(<JUV:PSDDI8RO-\G5#LUK',R9G7H4MJK-KE_N\)XD8J>3DONH1
M>U-R3JY+ZL(\TY/@C1^&>FPR_$L->RKUS'T/1(_S#*OVW2<+>/*,H6[4ENO9
M%[DL6>GGN<U*19N]</VU'?;F3Y\J#.VKM<27,ER(5L.W4*;\VQ7WW'(L`S7I
MX>F&"RM+9=6`ISHZCQ-<U'X;^'(P49+(<TEM[QJKXTIL3WTKLJ>SY']XWQEN
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MU9_AW=,VZVM:P=6_V_VQ%EWOW!SO++3,EX)M/@4:T8^UD.9'#;//@2[_`'O(
MLMOR+?8K3ZY&C%Q+KCSO9,E*JI*C;Z`=.Z&8]Z;NA6F'O-N)NWC/>1V)M-_Q
M^#O197MJ;-M?N'M[B^17F#87=Q<$NN+7FX6B^VG$YMQ:>N%KN+';*AE:VY'4
M@U1)-T0,S=TW>',]S(6\N";H2[1/W:V&WPS#;+*)ECMK=FMU^QF4XSE.U.70
MK4TMUN.QD^W]YB+*D$H<?:<4/"`=.@&M1[Y6[M^RG=:W[9V/$\L>S3O.O=U+
MNGV.\L/0,?7<]KL2=N^_^].X%_MJU7>[X1B%Q8EA,2+T+<5"3';6E;Y6E0&1
M=QK9WZ=EL/ON[]IWOP'O$JPFU2\JS'8R?LE;-M8F48Y9HR[ADEMVPS*P9+>+
M]9,FCVN.\[;479-P9E.MI:=*2O6J['L0.^X]Y#<3?S-<&VR[I5QQ#'8M]V5P
MC?\`W$WHW`QZ;E\+`<)W-[8;=8CCN#PKI98^0;C92S#E25^N36H-OAQ2M:75
M.(35O:#,>+8[W@=MK'N1?MR=^[%O';;=@=_NV+QCLW8MNKO9<DM%KN%R3*FW
M#'\BN,"]69UN,E'JRXK3B5:DNJ'"J^KU@Q3W8X_>NW5VJV'WMS'O'X\]:MP<
M(P/<3)<$MW=UQ>VL+AY%:X-WN.-0<K1ECD^&WTR2RW-#"G$C1?03PJLJ)@QA
MM)WMMVGN^#N3M1NPK&'=E,JWDW2V3V&OUILR+5<\8W*VGL^/98]@F97-+RV[
MO,S_``^_O2[2XL-N+>MCK:0KJX5<53KH#93!-T,LRKO%=Z';*\/6]S%=HU[)
M##6H\!N/<&1GVWKF29#\Y3TK*[CVET0"SU!/8M^B->=6TV5!GVJ`4`H!0'B<
M]^KST!PH!0&)KG_6,_\`GDC\8JM^'LKL.:O_`,3/M?SGAJ\QB@(F_P#]1W;^
M[Y7XHU?:]M>3YS4S_P""O?NG\S->JE3@A0"@%`*`4`H!0"@%`*`4`H!0"@%`
M8FWF`.'L@\1\^0/Q$VMW3_QW]E_0<QXM2>EQK_UE]V1:VVW>$S?;[L+>^\K)
ML;1TH-GNS[BGHC0X$6JY'M)$0`<FU=HUJ/>CG6;,TK'RO6CZEWBNGM1&>'O'
MFM:%3'NR_,Z<MUN;=8K_`$2WQ['5=1]-MDMP+#NW8KE>,>1/B-6VX1X5SC7)
MA+;T:8]$$D,LK;<=9EH#:O?I(3KX->%<AGX=W"NJ%VFU;*=)]!^%O$6#XCPY
MY."KB[N:C-323C)QYJ53:?:C/L>(S&'W-/I>%P\5GV?`*T3J#TZT`H!0"@*C
MD?-],4`/,^<^[0%*`4`H!0"@%`=;SS,9EV3)>:CQV$%U^1(=;889:3Q4X\\Z
MI+;:$CPJ(%$FVHK:V4E*,(N=QJ,$JMO8DNMFJFX_>GQW'R_:\#99RF[)"FU7
M9U2V\>AN:%)[(I*)%V6@_8=FT3]>:E\;2KD_7R'RPX=+]!YUKOQ!PL-O'TF*
MR,C=SO\`#79N<Z=5#17+,URC.+DJZY1>)=UDZJ[%#J^B'"022&8$)'3'B,I!
MTT2G4^$D\:G+5FU8CR6HI1/)=1U34-6OO(S[L[D^A-^JEPC'<EP^=EK5D-`[
M6)DNWNIG0)4F#,C)<<CRX;[L:0RL(40IIYE2'$'4>`U6D9+EFJQX%8W;EB7?
M692A>C6DHNC7E*X#WE;E;NPMF=QW+Q$3T-IOL)"4W5E/+KFQ?18N`3KJ5(+;
MOD4:OOZ;&7K6*1?!_0;>D^-;UEJQJD7.U]=>TOM+I\GF-P+#D=CRB`BYX_<X
MEU@K`U>BNI6IE9&O9263TO1GAX4K2D^2H>Y;G;ERS33ZST3$S<7/M*_AW(W+
M?4]W4UO3ZG0FZL-H4`H!0"@.*D)6.E0!2>8(!!\X((H"%E6A"R5QE="N)[-6
MI0=>?2KZT^3E0$`ZPZPOLW4*0KQ$<]/"D\B*`ZJ`4`H!0"@%`*`4`H!0"@.2
M4+4H(2E2E*.@2`23KXA0&X.U-G4K#+4Y)/2DOW#[DGWW":\-%*X@5$9?X\O)
M\QW^A_TNWVR^\S+333;*`AI"4)'@2--?*H\U'RGC6L2Q\_OVF?=FN?><[K>2
M6;%A.?S[;69_ZGX1:8C[J6\CG6*WRV;SC;T)*@Q,EW7'Y$@02L%3<U#820%J
MUZSP7K,=&UR%R[3\M>7=R;6V-6N62?0E*BEU-\#P+^Y+X<9/Q'^&F1C:;SRU
MO3I_G,>$6TKKMQDKEIQK24IVG+NJITN*-*59^+;H=X`,22LGI#?JS_:]>O2&
M^RZ.T[7JX=.G5U<--:^C&U1[J'X]\LZ\O++GW4HZUX4IOZC?/,]T<N[JN"X'
MW><*E61&;1%/;J[YN9)B&'YPS8=Q,\L]H39]NK/"S.R7^'8I&$8/"@IO*XK;
M3S]XE/-.J4(J`.5QL*SKF5=U?)4ORTJ6[/+*<.:W"3K<?)*/,IS;<*MTCM6]
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MCS8DME:`MF3$D-*0XDC5*TD5U$9QG!3@TXM5777=3M/$KMJ]CW98]^$[=^$G
M&491:E&46U)-;ZIIIK?54/T5;+=V&Z;"?LBN]/FN6-7&)FV_>U<G-Y]AE+?0
MU8<3B)C,83#7;5'H9NURMDM<Z4LI[4(DM,G[UI7@7CS7+>J:TK&/RO&Q:P4E
M^E+]/;P322[&^D_5[^U+X;97@7X=_P`YU57(:UKDH9,K<FTK5A1:QX\E:*<H
M-W9NG-2<(OV:&X/?/95W>'+7WM[8V^U@6>[#S>[-WG(4*.ZXRU9,CPRY,;'[
MLS&(R%*7(P7.YZ;+,>4E2DVN[CCTMUQ$>#/J`L[;>_H[N2NX[WF,TA7).R>7
M]QO;[NZ[IYI;[;/ND':2_6]5BS[;_+,R9MS$F7;L'OC\N?;I5Q[,LP9'8J>*
M4*"J/I[097[VG>!VL[QFSN2]UWNX9WBN]VZW>&B6_;Z-"VWN<?,;/@&&7RZV
M]69[G;A7RS&59\6QO%L99D/-^M/MR)DLLLL-K6O@2IZSW`QGWL]RSW!]]KSO
M=88LN?9.\5W7;OM7:X;;+SHN?>;V&M[2-BTNM,(7U7/-L;R)5O\`2])PP`-?
M1TJJ7,N%`3M^V=OG="VC[@^Y#-@OV9P^ZK/R-OO$,8Q;)=ZR9RS[^X;)M^[F
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M9/\`TWE9V]C_`*]Z_(<:%L^;^Q:7Z*6D](`K)NM.@%^8SL<]W@=N_P!H1@5G
MN1QS/H??KSS.MI,O2GIDX;N]@V.;;W[;_(FGATN(81>(HB2^E0[2!*?;Y*(H
M]K0/5^S_`-WSWA]VN]WN;*M$C&LHFH[ME@S[%YC#T:1B>YV&[8W/%=Q<7>0Z
MA!Z+5E=KD):5IHI@MJ'OJK))*BX@^F+C+C1Z7$E)\'A!\H/(@U8#KH!0"@/$
MY[]7GH#A0"@,37/^L9_\\D?C%5OP]E=AS5_^)GVOYSPU>8RBE)0E2UJ2A"!U
M+6LA*4I^R4I1`2//1;71;RC:BN:32B8VRK+8CL5^UVQ1?4_HW(EC@PEK7[HT
MR3Z3JEZ:=0T3IKIK6U9L/F4Y>RCG=3U2U.V\;'=6]C?13JXF+JWCFA0"@%`*
M`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('XB;6[I_X[^R_H.9\6_TN/[Y?=D:
MN5,GFI]1>X/^H^X/^;[=_P`#37(^(_Q[?V/^8^@O@Y_2,W_<P^XC?"N=/7Q0
M"@%`*`J.1\WTQ0`\SYS[M`4H!0"@%`*`4!H#WO,CO7^*;'BR;A(:L*,?8NKE
MN:<4W'E3I,^<R7Y:$D)DEIJ*D-A8(1J2!J370Z1;@K$KE$YN=-O0DEN/&OB3
MFY7\PM:>IM8G<J;CT.3E)5?&B226Y;]^TT[J6/-10"@.#OWIW\$[^+555O+9
M^P^QFL"N9]CW!4NCD'O?:7EM[?KMCV88_+M$U^&X_>+9$E-MN*2Q-BR9C,=Z
M-,9!#;[*VG"-%`Z'B-"*Q9$(W;,HS2]E]J)+2,O)Q-0M3QYN,G<BGP:;2::W
M-,^J92>I24@G0G0#B>D$@<O-7*GO35)-+B4((X$$'Q$$'VC504H4%4`H!0"@
M.IUEM]/2ZD*'E`X'Q@\P:`MZ5:'$`KCGM!\&=`L>97)>OMT!#J0I*BDI4%#F
M"""/'J#QX&@.-`*`4`H!0"@%`/;^CZ=`2L6U//@+=!:;/C^^*_@I.G3[-`7%
M'BLQDZ-(T.@!7J>M6GA*N=`;7;9_J7;/YQ<?Z:[4/E_Q#[$=_H?],AVR^\R_
M*UR6*@D$$'0CB".8-`1XM%F"@OYDLG6%=87\SVWK"]>H+ZO5=>L*XZ\]:O[R
MY]:7G?I-;\EA5KW%FO[N'S\I^47]K%W,LJVU[QDW=+;?$<ER7`]^';GF#[.,
MV"[W\XON`V\R<SM4U-JB37(T6\RI*+G$4X$A7K3S:2>QKW/P+XCQ\S25@YER
M$,K&?+64DN:&UPDFVJM+U7UI'Y<_W1_"#4_#GQ"N>)?#^+D9&B:VYY#5JW.[
MW.35?F(2Y%*BG*2NPKT3E']`QG^S<[E68;Z=Y/&Y6XF%Y7CFV6UJX6X>7/9'
MCE[Q]F_2K3<&7,9Q*&[=84+UAR\7IM#DCLBI3<*.Z>!*:W?&/B3'TW1IQP[D
M)YE^MN/+)/E37K2V-[E5+K:X'/?V\?!S5_&OQ$QKVO8>3C^'-+<<J^[MJY:5
MR4))V;$7)1;=RY1SINMPGQ1^PAZUV=]UU]VRV5UUY:W777+1;7''''25.+<6
MJ,5+6M2B23J2:^?E.Y%44I4I3VGZ3]:'AX<I.<K-ES;JWW<*M\7ZO':>I;33
MK:F7667F%I[-;#S+;L=QL:?<UL.)4TIO0`=)'3IX*M-@HZRP^TMB0PQ(CNIZ
M'(\AEI^.X@$$(<CNI6RX@%(]%22.`\5`<DH;0UV"&F41^R[`QTM-ICF/TE!C
ME@)#)CE!T[/IZ-.&FE`>&V6BS61M]FR6:SV1J4OM9+5FM4"TMR7==>TD(M\>
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MYVSQ::;:+[Q`"GGRA*2\\M(`*U:J(`X\!0'!N/&96\XQ%BQW)+G:R7(\9AAR
M4]Q';2G&FT+DO'7WRRI7$\>-`=BT)6DI6D*2>8(H".?@?7,JU\/9JUX>1)H"
M+4E224J!!&H((\7.@*4!XG/?J\]`<*`4!B>Y_P!8S_YY(_&*K?A["[#F;_\`
M$S?15_.6/>LMMEIZFFUB=-&H]784.S;5_P!>_P`4H`\('4KR5L6[,YOA$A\S
M5K&+6$?7O<%N\YBF[9%=+RI7K;W0QKZ$1DJ1'1XM1KJZKRJUK>A9A!;%MXG,
M96=DY;I<E2'!;B#K*:8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('
MXB;6[I_X[^R_H.9\6_TN/[Y?=D:N5,GFI]1>X/\`J/N#_F^W?\#37(^(_P`>
MW]C_`)CZ"^#G](S?]S#[B-\*YT]?%`*`4`H"HY'S?3%`#S/G/NT!2@%`*`4`
MH!0'SE[W?_N3:/\`)]N_XE=ZZ/2/X67[Q_-$\/\`B1_7;?\`MH_?F:KU*'`"
M@%`<'?O3OX)W\6JJK>6S]E]AK/'BR9TEN)"CO2Y3Q"6H\9I;SSATY(;0"H^?
MD*EJQBJS:4>LY2%JY=N*%N+E*3V45>DV'VZV7F&\62YY3(,-+5UMLEJTPU)7
M**FIK#J!,D\6V4A2?20CJ5^^%1N5GP[N4+*JZ/;T>0[?1/"MQ95J_J,N6ER#
MY([77F6][O(?41#+,?J0PTVVC4^\2`3QYD\2HGRDURK;EO/>H6X6ERVTHQ.#
MT=B0DH?:0ZDC3TT@D#]ZKFD^:JIM;BD[<+BY9I-%L3L><2%.05]H.?8.:!8\
MB%\E^8Z&LT;WUB*OZ=**<K&V/![UV<2VU)4VHH<2I"T^^2M)2H><$`UGJGM6
MXC'&47RR7K%*%!0"@%`*`\LB(Q)'W1`ZA[U8X+'D"M#KIY:`MV7:WHX*VP7F
M]2=4`]:1^^1Q/#QB@(LC2@%`*`4`TH#W1K?(D\4IZ6_A%'1)_@_9D#Q4!<46
MW,QNE6G:.`??%@:I/C2.0'B\-`2%`*`VEVS_`%+MG\XN/]-=J'R_XA]B._T/
M^F6^V7WF7Y6N2PH!0'8AUQK7LW%HUTUZ%*3KIRUZ2-:%RE*/LMHJX\ZZ`''%
MK`X@+4I0!X<M2=.5-@E)R]IM^<ZJ%HH!0"@%`*`4`H!0"@%`*`4`H!0'4ZRV
MZDI6D'Q*'!0\QH"*>@N(U4WJM/'APZQYP#Q'EH"$<]^OR*T/D/BH#A0':VRM
MP\!H/LCP'/3GX:`T_P`\R>YOW^^VMMP18D6YS8A$<J2Y(#+[B"MUW@L!?V*=
M!X]:GL:Q%6XSEMDXKR'EFL:CDSS+UB#Y+<;DELZ:/>S'%;:5"!%5`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`Q/O-^J#/]^0/Q$VMW3_QW]E_0<SXM_I<?WR^
M[(U<J9/-3ZB]P?\`4?<'_-]N_P"!IKD?$?X]O['_`#'T%\'/Z1F_[F'W$;X5
MSIZ^*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H!0"@/G+WN_P#W)M'^3[=_Q*[U
MT>D?PLOWC^:)X?\`$C^NV_\`;1^_,U7J4.`%`5`U(`YDZ`>$D\@`.))H$JNB
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ML0NJ6Q[&0]_!N6JRAZUOJW^4A/I<#Y_%64T.FG2*`4`H!0"@(Z5;F9/4K3LW
M#R6GPG3Z]/`*\_.@+=DP'XW%20I'PB-2CV=>*3K[%`>,`\/+X?H\U`=[,5Y]
M82T@JX@%7)"?X2N`!T\'.@+ABVEEG13I[97A21HVD^#0<U<?'0$MH!IH!PY>
M0:::#R4!6@%`*`VEVS_4NV?SBX_TUVH?+_B'V([_`$/^F6^V7WF7Y6N2PH!0
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M?1Q9UC/2'G6""A2U$$U0&OVR^ZV=;D[L[UXU>(L2#AVV^X.4X)8Q$V]RN`)_
MS#*LC,>X+W+N%]D8MD%R<;G/>LVZ'`9=C$H)7HE74!";2=X+)=PCW8/G*T8_
M&&]^U&Z>?Y/\V&:HV:XX#<,0@08EG#LM[LX$E[(76Y!?[18=0A(4DZ@@71M1
ME.\=_P!X-U\+S>^[:3L7VUFXA;V?\+87DMDOUV7G.+1\IMTAZ?=,WOL"*BSH
M=5'>0F,HR2D.)4T/1JO0"VML-_\`),Y/=M3<+5CL5>\]MWVF9$B"J:5VIS:>
MXH@6Y%H2[+=*$R%N!,SMPX4KT2GH)TI1@LW:'O*YYN!WBLJVFN-LQY>/6B];
MZ0_XKB688W<[%9MJ,TM&(8_>F,POURDXKN6<FFW)3$^-9V&W;.^$E\I2H!1I
MKL!DK9#=/<+<K-MW8U_@1;=B&#Y_GN#X\F/M[D]I9GC$<OF8[%FL[CW'(YN/
MY7,=C0%KFQ(ENBJBNK`*B$D$^CL!=N\FX&38A(VOQ;#$8Q&RC=O<!6"VG(<U
M1<'\5QKU+%,BS&=,FV^US+;.OEYN$''%Q+5;D2H@ES74]3R4H4E2C8,-7SO#
MY]C&RG>FR2Y6W#[MN1W9[M<L<7=+%"O3N!9K<$XYB>56R=%L:KF]?($^);\M
M;B72T(GO.Q[C'6VB0I*T]-`;+;:7;([[A5GN^6*4;Y-,U<D.8/?]MWD--SI#
M,5N3A>476]7VS2$QVT]0?DK[74.)"4J`H"^J`4`H!0"@*CG[!]PT!;LEE#CK
MFO`AQ?%.@^N//AH>5`="8R$G4ZJ\0/`#S@<Z`]*>8`X`$<!P'M51[@:$9G^M
M^4?W_=/Z6Y72V/P(?97S'CNJ?U+(_?2^<MNLQH"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0&)]YOU09_OR!^(FUNZ?\`CO[+^@YGQ;_2X_OE]V1JY4R>:GU$
M[@_ZC[@_YOMO[MC2*Y'Q'^/;^Q_S'T%\'/Z1F_[F/W$;XUSIZ^*`4`H!0%1R
M/F^F*`'F?.?=H"E`*`4`H!0"@/G5WO674;B6-]3:TL/XC$;8>*%!MYR/<KEV
M[;:M-%+:[9'4.8ZAXZZ/2&GC22Z+C^5+T'B/Q)A..MV9M/DEC*CZ-DI55>.T
MU2/#G]'MU*'GQ==@PZ\7\I<9:]5A$\9TI)2T4@CJ[!O@N0K3['T?&16.Y>A;
M33VLDL'2LO.:G;7+9;]IK93JXF:[#AUGL(2XVUZW.`U5.DI2I:5?[NUQ1'3Y
MM5>6M.Y?G<5-RX([+!T;%PDI+UK_`-9KYET%U+)*5$GZU7[H.OLFL&XE:*C[
M#%_BK96XA62%H0IR[6QM"2I:KA#"4I&I4?6&SP`XG0"K;C2@Z\&9<=-Y-M+:
M^\C\Z-M5>^5YS42>AO8SC52@H!0%02*#IKTD7-M,6=Z13V+Y/!YL`$GE]T3[
MUP>T?+5\;DH]AJW\.U?V^S/BOI1:,VURX)*EH+C/@?:!+?'CHL<2@@<]:V(W
M%/M(:_BW;#K)5AQ1&U>:Y6A04`H!0%-!RT&GBT&A\XY&@/.8D4GJ,=DGQ]FG
MZE`=Z4I0-$I2D>)(`'M#04!RH!0"@%`*`SW8,[P;;_;NSW?/<TQ/![4_-N4>
M/<<OR*TXY"D2!+=46(\B[RXC<AX)()2@J4`==*C[F+DY65*&+;N7)T6R,9/S
MT6SRG5V-;T70M$M9>N9F+A8KG)*=^["U%OF>Q.;BF^I59E6TWBSY!;8=YL%V
MM=]L]P93(@7:RW")=+9.87[UZ)/@NOQ9#9\:%D:UI7+=RU-PO1E":=&I)IKM
M3VHZ+$R\3/QX9>!=M7\2XJQG;G&<)+C&46TUUIGAMN68K>;U?,;M&3X]=<CQ
MA3"<EQ^VWJW3KWCQE`F,+Y:HLEV=:C(`]`/MME7@UJZ=B_;MQO7(3C9G7EDX
MM1E3ZK:H]FW88,?5=+R\N]@8F3CW<_&IWMJ%R$KEJN[O(1;E"O1S)5%SRO%;
M)=;'8;UDV/6>^90\]'QFRW6\VZWW7(I$8-F1'L5OER&I=V?8#J>M$=#BD]0U
M'$4A8OW+<KMN$Y6X>TTFU'KDTJ176Z(KDZIIF'E6,',R;%K.R6U9MSN0C<O-
M;U:A)J5QJJJHIM57$CGY&`;@HR/#I,G$LT38;C;&,NQA<NUWU5CN\&;&OEF8
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M'FE=G.,;:C]9S;45'_4W3K/9MYF6TM]@(QS:G,<`R"W8M;X<<6;!LFL=^;L-
MKU5'@(>CVB?-7!BJ4V4-ES0*((!)K+?P\O%2>3:N6XRW.4913XI52-#2O$7A
M_793AHF?AYD[<4YJQ>MW7%2JHN2A*7*I--)NB='0\<7<'9+%<ENN'Q,]VMQO
M+[KDDFXWK%D9;BUJR.=E]X3&=E2[C957%FXNY!=4)9*BMOMWAT<^%7+`SY6?
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MNVR1N4(=MO>23G&D7)"GDNR7B@.`KZ:/$RU>6/W5SOVJJ/*TVN*35:;]IB_\
MD\._R^YJ_P"?P_Y5:GR3O]];[F$TTN25SFY(RJTN5M.K2I4[TXGLKMC+R/=E
M-IP'`I%\4]<,KS]YZVX_%N3F0SH[\B?>+S)DQ[<IR]W%;2E.K4%2'E).I*N.
M.W:O7[BLVHRE==4DDV]E:[-^RC\QO9>HZ=I^'+4<_(LV-/BDW=N3C"VE)I1;
MG)J*4FTHU>VJIO.SYQV5W[Q^\XTW=-M-X\8:>@*OMH@W7'LUM<.8AU4NTOS&
M[?)G)MUP9?8+L5X%M]M:"MI0*=1DOXN5B-+)MSM.2V<T7&O95+I-72]?T+75
M.6AYN)FJU3G[B];O<E=W-W<I<K='1/?1T+;ML[NRVV`_L%:;OLE"@+D3;%+V
M@C7S#T*D3Y$LR[E;)^)&;ZY-NLN?J[(2\TN2Z^>I?4K4U?\`D<YVOS'<W78:
MKS<DN6G&M*4-=>*?"\M0_E$=2T]ZLI\CL?F+/?*:WP[OGY^9=,:5ZC.;[[;#
M3\F4^VPPPT[)DR)#B6F6&&4*>???=<4EMIIEM*EK4HA*4@DG2M1)MI+:VZ+K
M;V)>4G+DX6H2N76HVX)N3>Q)+:VV]R72WN6^A#8[DV-9A:8]_P`1R*Q9589:
MWFXM[QN[0+Y:)+D=PLR&V+E;)$F&ZY'=24K2E9*%#0Z&LMVS>QY]U?A*%U+:
MI*C5=VPU-/U+3M6Q8YVE9%C)PI52N6;D+L&TZ-*<'*+::HZ/8RV[ENSM39LB
M.(7C<_;RT9:)$6(K%[IFF.6[(4RIS;3L*,JSS+BS<$R)C3R%-(+?4XE:2D'4
M5FA@9MRS^8MV;LK%*\RA+EHNNE"/R/%/A?$U#^4YFI8%G5.:,>YGD6HW:RHX
MKNY34N:2:Y8TK*JHF3^0Y9BF(HMKF69/CV+MWFY-6>T.9%>K=96[I=WQJS:[
M>Y<I,9$RXO#WC#94XK0Z`Z5AM8]^_7N(3GRJKY8N5%Q=$Z+K-W4-6TK2E;EJ
MF3CXT;UQ6[;NW(6U.X]T(\[7--]$55O@<H^58M+R2X8;%R;'Y.86B$S<KMBD
M>\V]_)+5;I'9>KS[E9&I"[E!AR.W1T..MI0OK3H>(U=Q>5E9+A-8\G13H^5O
MJ>[90NAJFF7=0N:3:R;$M5M04IV5<@[L(NE)3MI\\8NJHY))U5'M1/5B-XJ.
M?L'W#0$$]]]=_"+^V-`==`*`TKW5L$FQ9A<GG$*]3O3[ET@/Z>@Z)!"I+/4.
M':1Y"B".>A!\-3V'<5RS%5]:*I0\K\0X4\34[DVO=79.47QKO7D?1UF.:W""
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@,3[S?J@S_?D#\1-K=T_\=_9?T',
M^+?Z7']\ONR-7-0.)X`<ZF3S6J6U[C[*=T;;R?@6TT>1>([L.\9E<%Y-)AOI
M*'HD%R.U%M##R%`*;>7":#RDD`CM0#H17#:UE1R,UQ@ZVX+E3^5_*?4/PUT2
M_HWAN,\I..5E3[R2:HU%I*":Z'RJOE-H:B#T`4`H!0"@*CD?-],4`/,^<^[0
M%*`4`H!0"@%`6QE>*8OF-K<M&56J)=82P2TA]&DF,Z1H'X,ILID1'QI[Y"AK
MIQUY5EM7[MF7/;DTS0U#3,#5;'Y;/M1N6NBN]/C%K:GV>4U*N7=GMM@EOW2P
M*E9'%2ZIV-:KF6C+AMCDA"6TH9N2D'D5:*&GO5'C4M'5I75R7$HOC_C<>?7O
MA_CX5QY.*Y9$*U4)TK%=5/;\M&6ZMIQA18<;4PXR>S4PM!;4R4<.@MD)+93I
MIIH-*RUKMWF&G*^5QY9+HI1KJ.%"IQ5[U7\%7VIH'N?80&/X3>;]TO!OU"`?
M_&RD*2'!X?5F?1<?/EX(\M73OP@NLUL32\G+]9KDL_6?3V<3-UAQ.S8^D*BL
M%^9IHJX20E<GB-"&M!T1T'Q)`)\)-:<[L[GM;CI\33L;$VVU6Y]9[_)P\A<M
M8S>%`*`4`H!0`\00>(/,'B#YQX:=F\;]Y!3K#'DDKC'U9T\TI!+*SY4^^02?
M".'DK+"ZX['M1'7]/MSK*UZDOD?H+3DPY,-70^TI&NO2OWS:_P"`L:A7NUL1
ME&6YD3=LW+,N6XFOF/-53$*`4`H!0"@%`*`4`H!0'S@W$E[$X[W\!>N_A;(4
M[8JX[%VR'W=+EN%:[E>=H;5E#,]E>>QYD*/'EVU.1/3DRSU/-J*5+:4H#J84
M.TPXZG<\+NWX8DUJD<EN^H-1NN-%RM-T=*4W;]J3WGS7XDGX)POCF\KXVVHW
M/!5S1H1TJ63"<\&%U23R8N*3AWKFKCK.+HW%O?!GU"[OFY/=;Q3NOWC<CN^0
M8N.=WC`!N;D:66K3><?@$XY,NE\R:=;F<D")[]MNTD%<-XJ+;C+K:$=/3V:.
M+U7"UJ_K4</5'S:K=[N.]2?K445LW-?I+?6K?%_1_@3Q'\,]+^&E[Q%X#C#'
M\`X*S+J]2Y:C[ISNWG%7?6E&<O8G5IJ48JE.5?$[N4[B;@[;]Z+9#O!;C[?;
MBX79>^_=]R\<SG<#+!!9P+.[]N%D#^8;0.X>XU-?FMM6*.PQ#(EM,%Q"RIKJ
M3J1Z-XCP\7,T3)TS$NVKES3HVY0MQ]N$8)0N*7&JJ]GE/C?X-^(=>\/_`!,T
M?QSXAP<_#Q?&5W+LY.3?Y5C9%S+N=_A.PU)R7)ZEM<\8U3;C5-FWG[5#;C)M
MV.\=W#<`P?(E8CN!=W]\)F`Y$A0:7:\WQJTXUE&+.+=U"F8\B^V5AEU8]XAP
MJY`@P7@?+L8.D:GEY,>?%CW2FN,).49?(ZGJO]SWA_4?%'Q"\$:)HM]XNO7/
MYC+&NITY,BS"S?L]B=RW&+?16NZJ<W^R>S[)MT-S._7GF>8X<0SF_;K;=KSO
M&%I+;MFRZV8S>;+DT);2D)<8`O-N?6A!![-*@G4Z:G!X[QK.%B:;B8L^\QHV
M)\DN,7.+3\S53?\`[6]=U+Q)K_C77-<Q_P`IK-[4L7\Q:=?=WX6[D+T=M*+O
M8SHMRK2N\U\M5S[H&*=Y;OS,_M*;+9)>YMVS^7/VSN6Y]BO][M%TV,5!?;Q:
M!M*NWQY*8MP3$[(-F&IM_7H2VXEQMX"7N6]>NZ1ILO"$I+#5I*YW<HIJ]7:[
MM=OD==U>!P6'D_"G3OB'XTM_W#6;4O$<\Z4\2>7;O7(2T[E?<1PN1/EFHTHX
M4EN49*49F_O?`GX)<_V7.[-PVQM[EKVVE=W>R+P6UR+=,M#]NQ1+^.-V2`_;
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MY/+$9+9IUKR)>[3N2?\`J?C`3(M5T8<&+M6KYP,,E#P+G8I=\)37K<)Z2_%^
M)&4<C^;O$CRM-=UR\DFTUOYEMVKBMA^?F3:\?_\`Q[\07+%W25\//_(+JNVY
M0N_GN]_-66G"2]SR5[O?M45))[4?:+]IIT?_`.9VYW6/0_P5LR=-0!^M^`Z=
M))Z=>`TKSOP97_S&RZ[>]O/_`.F9]@?W(4_^.>H[J?E-/_\`S8R./[,>Z;5R
MMOLQ@87?^ZW?,N9?Q&5E1[L6&WK#HD6S.6-,?'V=PFKW'9=NN6-W%JX!<AHE
MHZJT`U-/&<<U9=J63'-C9]91_,2C/UN:LN[:I2%.6D7U;2[^VV_X:N:#EVM(
MO>&KVJJ5B5[^46+EB,;?=N-K\RKBK*_S][ZT6X[TCXJ;\XFY<MV^^!D]XP[!
M+5MM!_:`8E8LZ[QR84NY;M[&MSKN_+8E6")$D0PSA]W3&4F4^MP@3.A/3U*2
MI/HVF9"CIV#8A=N2S):7*4,?=:O-)*DF]\UO2X;:[#XX\<Z3<R/%7BG4LO$P
MK7AZ'CBS;R-52<LW3XRN2ES6XQ:]S-Q:DZ^W14JTU]X?VD>[\O;;NAY5;\)D
M.WK.-\UV#8[;!NUOMR;E?[IN6@VYZ99RTXGU^4YC`DN-J;/2MQULZZ*KR_P?
M@1S=?MO)7+C8U;URJHHJV]B?#UTMF_8S[@_N'\5W/#OPHRL?1Y=]K&MRMZ=A
M\C3G=GE^JY6Z>TW9YG%K>Y1?2:P_LM+Y.VGS[?\`[H&1X1F^U*+&O'MZ=K,`
MW,5;DYA$Q#(;9;[!EI<%KESK;(CN9%!:EH4PZM($E75HH*`F_&]N.=BXOB"W
M=MWW).U=G;KR\Z;<:U2:?*Z;>'8>:_VR:A>\-:WKOPIU##S=,5EVM0P\;,<>
M_5F["-J_7DE*+CWL83]5NG.Z[:I:K]X+N[;@]YKOM]_K;?;3:O:#,KW=+3L-
M%D;D[EWU=DO>RB9.*6-Q&4X0F+!ES;A<;@U#<9DMM=*NS;0-%A729[2]6Q=&
M\.:7EYE^_;MUO^[MQYHW:2?JRZ**O2F>7^./`.N_$?XS^.=`\.Z7I>9F3AIJ
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M0BCZBUQ1]*E1S]@^X:`@GOOKOX1?VQH#KH!0$+?\=L^3P%VV\Q1)8)ZVEI/1
M(BN\NVBO@%3+FG`Z:A0X$$5DM79V9<T-_P`_::F;@XV?9[C*BI0Z.*?%/>F:
MQY?LY?+)VLRQE=^MJ-5J;:;";G&;&I)<CH)3)2D<U->EXTBI>QG6[FRY2,S@
M-2\+Y>'6[B5NX^^GZ:XU73Y##A!25)4%)4E12I*DE*DJ2=%)4E0!2H'@0>5;
MR=54YEIIT=4^O84JI04`H!0"@%`*`4`H!0"@%`*`4!Z(L25.?3&AQW9+ZSHE
MME!6H\-=3I[U(\).B1XZME.,=LMB,ENU=O2Y+47*;Z%_C8NLRC9]M@I`=ODE
M:%D#2'"6D%`/$=M(*5@J\B1[)K1NYM'RV]QT>+X?]7FS)-2^K%KY7M%XVV"6
MR[9)*EK2-3$FJ3JO3P-24A`"B.&BAQ/UPJEO-JZ7-Q3+\/I1YL-MR^J_HE_D
M8)S;;/.<[@QL7QG'ILZ[_/<%Q]"TB-&@QT-2TN2YTU_ICQXK96/2*CU:CI"B
M0#*XV9C8\G>N2I#E?E.*UO0=7U:S'3L&Q.67WJ;3V**Y9>M)O8EUU-AMG.YO
MBN$R(.1Y]*9S+)(RFY,:V(:*,7M<I&BD*[%T!^\/QW!JE;H0UU#4-G@:C\[7
M+M].UC+DLOI_2:^@ZSPQ\+]/TF4,[6)1RLZ.U1I[J,N--\VO]5$GN1ND23SY
M^P/:`Y`"H$]4ZRE`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H"BE)2-5$`#PDZ
M4!X'9AXAH</LR-?_`*0>%`>!2BHZJ))/A/$T!2@+<R#$[)DK>EPBA$E*=&I\
M?1J8W]B"YH0\VG[%8(\U9K=^Y:?JOU>!'YNF8F='WRI=Z)+8UZ3"L_:;(6)@
M:M[L.=#6K5$M3R8RV4D\!(85U*ZD@_[,K!\G*MZ.;::K+8SE[GAS-C<<++C*
MT]S;2\Z,B8]MI9K*CUF?T7BX!"U!;S>D)A703]PBJZ@M23R4YU'P@"M:YE7+
MCY5LA4F\+0L7%CWM[WMZG3[*?4NHMH^UIX.`'#Q```<*S5JC4HEL6XI52@H!
M0"@%`*`4`H!5`<'&T.I*'4)<0>:%CJ2?8/*JIM;MY248S7+-)Q+;FXZ#JY!5
MT\SZNX?1/X-P_N!59H7FMDB+OZ:O:L-TX/Z"UW6G65EMYM32QS2L$'V/`1Y1
MJ*V$T]J(J4)0?+-4D<*%HH!0"@%`*`4`H!0&R>$66RW_`&_M=NO]ELU_MXF3
MWA`OMJM]X@A],U[I?3$N4:5'2\`>"@GJ\M1>1=NVLISM3G"=%MBVG3AL:.UT
M["P=0T:W8S[%F_8YI/EN0A<C7F='RSC)57&E3(;EOMKMO-H=MEN<M!B^HJM#
MD"(NU*A`%(AFV+95!,0)X=EV?9Z>"M53FI]XI25RM>:OK5XUWU)J6-C3Q_RD
M[5N6*X\K@XQ<.7ZO(URTZJ4ZCH>LMDDQH,*39+-)AVMR.]:X<BU6]^):WHB>
MB*];(KL=3%O>BHX-+92A38X)(%7*[=4G-2DIRWM/?V\2R>%A7+<+-VQ9E9M-
M.$7"+4''V7!-4@UT.-&CMD6VVS)<.?,MMNF3[:IU5MGRX$23.MJI`"9"K=,?
M:7)@JD)2`LM*05@:'6J*Y<C%PC)J$MZ3V/M1?/&QKMZ&1=MVYY%NO).48N4*
M[^233<6UL;BU7I*QK;;(,B=+@VRW0I=T>3(N<J'`AQ)-SDI!2)-QD1F&GI\@
M!1T<>4M?$\>-)7+DHJ,Y2E%;JNM.I<$4M8N+8G.[8M6H7;KK.481BYM=,FDN
M9];J^L\EUQ[';ZY">ON.V"^O6U17;GKW9+7=WK>LJZ^N`[<8DER$KJ&NK92>
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M\0V`EM%Z*HI-W0VD:)$GM0D<M*IWUU))3FE'V=K]7LX%SP,"7>5L6/?_`(ON
MX^]IN[RJ]>G1SUIT'NC1HT.,Q#A1HT*)%:2Q&B0V&HL6,PV.EMB/&80VQ'9;
M2-$H0D)`Y`58VY-RDVY/I>\SVK5JQ;5FQ&,+$52,8I*,5P26Q+@E1+@<9<.%
M<(K\&XPH=Q@RFRS)@W",Q-A26E$%34F)*;=CR&B4CT5I*=1RI&4H24H-QDNE
M.C\Y;>LV<FT[&3"%RQ+9*,XJ49+@XR33\J.UAIF*TS'BLM18\9M#,:/&;;CL
M1V6DA+3,=EE*&F&FD@!*4@)2``!H*.3E+FEMD]Y="$+4%;M)1MQBDE%422W)
M);%3@J$5_AS&_F^19_\`#>._,\N0J7+M'S%:OFF7*6XAY<J5;!$$&1*6\VE9
M<6VI94D$G4"LG?WN=7.>7>K9S5=:<$^A&K_+=-_+2P_R^.L2<N9P[JWR.5:\
MSAR\K;>UMQJ^)[9MNMMRAKMUQMMON-M=0VAVVW&#$G6YQ#*D+9;<@RF78CB&
M5MI*`4:)*01IH*LC<N0GWD&U/BFTZ\:K:;%_'Q<FR\?)M6[F.Z5A.,90V;ER
MM.-%T*E#R6O'\>L7;&Q8]8;$9/9^LFQV6V6?UGLNKLO6?FZ+&]8[+K/3U]73
MJ=--:NN7KUVG?3E.FZK;IYVS#BZ?I^!7^7X]C'YJ5[JW"WS4W5Y%%NG14+Q_
M'76KI'=QW'W8]\=#][CNV2UN,7J0DA2)%Y97$+5UD)6D$+D!Q0(U!U`JO?WJ
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M6[T\FW;MQR;E.>:C%2G3=SR2K*G1S-T6Q'K4E*DJ0M*5H6E2%H6`I#C:TE"V
MW$*!2M"TD@@\"*L[#*U&47&23BU1I[J<&>6!;[=:HC4"U6^!:H#'7V$"V0HM
MN@L=:RXL,0X;3,9D+<45'I2-2=3QJZ4YSES7&Y3?2W5OM9BL8^/BVE8Q;<+5
MB.Z,(J,5V1BDEY$>NK3,5'/V#[AH"">^^N_A%_;&@/#+G0K>V'9TN/$0=>DO
MN)1U:`'T4D]2O8!JJC*6R*;9CNWK5E<UV48KK9',9+8)"PVS=X96HZ!*UJ:U
M4?`"ZE"?W:O=JXE5II&"&?AS:4;D*LF^>A'$$:@CB"/&".!%8^TVJ[*E=3SU
M.M"I866;<XYEH6])CF!<R-$72"$MOJ(][ZVWH&IB0>?4`KQ$5LV<J[9V5YH<
M&0^I:'@ZDN:<>2_39*.^O6MTEU?*:PY7MMD>)E;[[!N-K3KTW2"A;C*4Z\/6
MVO2=B+TYE7H:\E&I>SEVKVQ-*7!G`ZEH6=IK<IKO,=?IQW=C6^+XUV&/ZVB$
M%`*`4`H!0"@%`*`4`H#DE"EJ2A"5+6HZ(0E)4I2CR2E*022:HVDJLJHRD^6*
MK)]!D.Q;>SIP;DW9:K=%5HH1P$JG.I.A&J5:HCA0^RU5Y*TKV9&.RWM9.X6A
M7KU+F5ZEKA^D_-N\IEVVVBWVA@1[?&;81H.M6G4\Z1]<\\K[HXKSG0>#2M"=
MZ=SV]YU&/C6,2')CQ45\K[62C;;CJPAI"G%J/!*023[0X#R\JQ&RHRD^6*JV
M7)#Q\^BY.5IX>P;5^XXX/!Y![=6NXDFD2%K!Z;K\B+MA*,,@1M&DI3H$)`""
M!]DGZ[V>-8FV]Y(1C&"Y8I*/47$Q<6G-$NZ-+\!&O9D_PB=4>S5"XD?+X_H]
MF@%`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4!XW9B$<&_34/#]:#_\`E0$>XXMP
MZK43Y/`/,*`ZZ`4`H!0"@.*_>.?@W/M%55;UVELO9?882J06XYE[Q52@H!0"
M@%`*`4`H!0"@%`=$B-'E-]G(:2X..AY+3Y4+'I)(I%RBZIF*[9MWE2XD_G\Y
M:DZP/,:N0R9#7/LCH'D#R:<'!^[Y*V874]DO:^0BK^G3@G*T^:/#I_S+?(()
M!&A2="#P((\!!X@UE(ZC%"@H!0"@%`*`4!M+MG^I=L_G%Q_IKM0^7_$/L1W^
MA_TRWVR^\R_*UR6%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`\LV="MD5
MZ?<9<>!"825/2Y;J&&&TZ'BIQ9`UTY`:D^"KHPE.7+%-R9CNW;5BV[UZ2A:6
M]MT7^.HPW>=R([J5_P"'DB0V_JXU<GT$-J0OTD+C,*"5*!2K4*7IYJVH8S3K
M=\WI(2_KD'%/"]9->TUL[4F8PES)4]Y4B8^[(>6=5..K*CY@#Z*$C7@``!6R
MDHJBV$#<N3NRY[C<I=?T'F^G52PNBRY;=K-TLI<];A<`8<A2B$CC]X=XK9/'
MD-4^2L<[4)K=M-_$U+(Q/57K6OJOZ'T&7;-D]JO8"67NPE::JA2"$/:GX%7O
M'T_P>/DK1G:G;VO<=)C9^/E;(.ESZKW^3CY"X:QFZ.!!20%)4"E25`%*DJ&B
MDJ2>"DD<P>!H'1JC1B#+MGK%?B[-LQ38;HH%12TCJM<EPZ<7HJ?2CJ4>:FM!
MXTFMZQFW+>RYZT/E.9U+PQB9=;N)2SD=7LRKQ71Y*&M&18E?\5DF/>8#K"5$
MAB8V"[!D@'@6921V9)'UIZ5CP@5+6K]N\D[;VG!9NG9>GS[O*CR\'OB^Q^DM
MNLQHB@%`*`4`H!0%"=.-`VEM>XN^Q87=[T$/*1ZA!5Q,F0@A3B?]W9/2MWJ'
M(G1/EK6NY-NWZN^1*8>DY.7ZS7)9XOI[$9ELN,6FQH!BL=I)TT7-?T7(/C[-
M6@#*#XD@>4FHVY?G<V/<=7B:=BX<?=JMQ_I/:_\`(N#GP'$\!P&IU\PYDUAH
MS?["=A6*0_TN228S//I(';+'B"3J$`Z\S5DII;%M9MV<.=SUKFR)=4:+'AHZ
M([:4#ZY1]):_*M9&IK'*3EO)2W:MVE2VJ?.>BK3(<T<_8^F*`[:`]4>8]'/H
MJZD>%M7%/L>(T!-,367]$Z]FYRZ%$<>'UJAP4/:-`>R@%`*`4!4<CYOIB@!Y
MGSGW:`I0"@(^8]R:2>&G4O0^^X\$\#RTH"/H!0"@%`*`4`H#BKWB_*A8_P#L
M-56]=I26V+[#"9&A(/,<ZD%N1S&\I52@H!0"@%`*`4`H!0"@%`*`4!;&0P4A
M`G-`!06EM_\`?!1(0YPX=6HT/C'&LUJ>WE>XBM1L1Y>_BO6K1^7I+4K8(@4`
MH!_TGV!S]J@,59?NYC>,*<AQ5B^W5'HJBP74^K1UZZ$2YR0XTA2=>*$!:_&!
M6Y9P[MW;+U8<?\B#S]?P\*L+?O;ZZ$]B[7_C@,0W;QO)RW$EJ%BNR]$B)->2
M8SZSPZ8DXAMI9/V*PA7BUI>P[MK:O6AU>@:?K^)FM6[GNK[W)O8^I/=YS*OB
M\NFGEUY:>/6M,G=YM/MJA2,,M74".IV>XG4::I7-?Z2/&"!41E_COR'>Z%7^
M66Z\9?>9?5:Q+B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%"0E)6HA*$@J6M
M1`2A*>*E+4>"$I',G@*#KZ#!>;[[8[CA>@X^&\DN[?4A3C+O3:(;@.A#\M&I
ME.(/-#7#]^*D<?3;M[UIOEM_*<CJWB[`PG*QB>_OK97=!<:OI[$:\O-;@[KS
M1.N\MU-M"SV+DA*XUHBI)T4+=`1P?6`??`*)/OEU).>+@1Y;:K<^5]K./C9U
MOQ)>5[)E)6-Z;JH17^F/3V[^LRHK$9=N@Q&XKOK[<>*RTI24%M[[DVE/7V74
ML%)`Y`ZBHY7E-MM4;.K>EW,6Q"-I]Y&,4NO8J;B!(*20H%)!T(4""".8((!%
M7FEN='O*54"@*I44D$<%`@I4"04J'$*20000?#5.W<-VU;R_+'G<^`$1[DDW
M"*G1(=*@F8TGEP</HOA(\"N.GAK!<L1DZQV/Y"7Q=7NV?5O^O;X]*])E>VW>
MW7=GMH$E#VGWQHD)?9)^M=:/I)/'GQ!\!K4G"4'229T5C)LY,>>RZKAT^8DJ
ML,YYY<2+/C.0YT9B7%>!2['DMI>96"-/2;6"G4>`\Q58MQ?-'9(LN6K=Z#MW
MHQE;>]-)KY3`>6;',/%V=B$@1G#U+59IKA,=9'$)ARSJMGAR0YJG]\*DK&H.
M/JWELXKT'&ZCX2A*MW37RO\`Z<MW_"^BG!^<UXN5KN-GEK@W2%(@2V]>IB2V
M6U$`Z=39]ZZ@Z\%))!J4A<A-<T'5'$W\>_BW':R(N%Q=#/!5YA%`*`4`H#+.
MWN/0I$=R]3&4274REL1&G4A;;(9">MXH.J%.J6K0:CT0*C\R\T^ZCPVG3Z%@
MV9VWF7$I2K2-=RIO[69;J.>UG3[R2AVJ5,T4$AIG4:O.`@'^`GWRSI[%6N44
M;%K%NW=M*1Z^DNR';(L+BA':.Z:%YP>G_P#(`=$#S<:Q.<FB3M8UJUM2]?B2
M!.M6FP*`4!S1S]CZ8H#MH!0"@)FW2%J465DJ!05H43KT])`*==>1UH"7H!0"
M@*CD?-],4`/,^<^[0%*`4!#2?O[GG'VHH#HH!0"@%`*`4`H!]'T<J`QS?[([
M%>=EQVU.175%Q70.,=:CZ06`/O95J4GV#6Y:N*2Y>D@\O%E:DYQ5;;^0M:LQ
MI"@%`*`4`H!0"@%`*`4`H!0$7>?ZLE>1+>G_`&S0J^W^(C5SOX2?53Y_\RP:
MVSG10"J@U1WCS;(4Y!<,7C3E0;1%9B=;4/J9>F&3%:D+]:D)(=6V"[H$`A.@
MX@ZU+X./:[M7FDY/<<+X@U'+_-RPX3<<>,55*J<FTGMZNHP+YN%2.U[SF!IK
MPTU\G`_N&E:#?LWHV=[N\_,<HR^U8;ZT[*QZ6F9VTF>%O"U(BQ'9*O5)2SVA
M)#)2&=2./UO.HC4XV+5F60DN\7#I.S\(W=0S-2MZ<I-XTZUYMO+15V/R4H?6
M.%$8M\.+`C([./#8;CLHX:A#20D:D`:J.FI\9-<?*3E)R>]L]_M6H6;<;-OV
M(JB/35ID%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"H!/`4'SF,\VW6Q3"4N,29/
MSG>$CT;-;G&W)"#IP]=>U+,)'$:]1Z].236YCX5[(VI<MOB_HXD%JGB#`TM.
M$GWF2OT(M5_XGNCY:OJ-0,VW8RO-2N/(D_-EG)/19[<MQMA203T^NOZAZ<O3
MGU:(\214WCX=C'VQ5;G%_1P/,]7\1ZAJK=N4N[Q7^A%M)_:Z9>79P1-;6XQ9
M[K&F7:Y1A,>AS1&C,/:*BHT80\75L>]><ZE\.K5(`Y>$:^H7[D)*W!TJJU\I
M*^%M-Q,FU/*R(\TH3Y8I^RMB=:=+,]H]'I2D)2E.@"4@)2E(\``T`2!X*B-^
MU[SO*+8DDDN!,LG[DWI]@C]Q(JY;#,MR(:]6N'*B29"VDID,L.NH>1Z*R6T%
M6CFG!P'I\/&KH2:=.@U,S'LW+<KDDE<C'>8N]WP^?PUM'.(4`H!0'='DR(CR
M)$9YQAYL@I<:64J&G@U!XCR<C5&DU1EUN<[<U.W)QDNE&3;)N$?0CWMK7D!/
M8''Q:R(_`'RJ1IYJU9XRWPW\">Q=9=5;RUL^LOI,FQY,:8RB1$?:D,+`*7&5
MA:3PX@D'5)\8.A%:K33HR>A.%R*G;:<7P.ZJ%Q#WO'[-D<14*]0&)S)UZ%+'
M3(84>'7&DI^[,*'[T^<&K[=R=J7-!T-7+PL;.M=UDP4H?*NQ]!K?EVRMTMH=
MFXRZN\0QJLP'`D71A.O$-]/2U-0D>+I7I];4M9U"$J1N[)<>@X;4O"N1CIWL
M%][:6WE?M+LX_.80<:<9<6T\VXRZVHH<:=0IMQM8YH<;6$K0H>(@5()I[5N.
M3E&4).$TU-;&GL:?6N@X54M%`*H]JH#83;*%)F8\E+#94!/FZN$:-)]-`)4O
MEP\FM1.:UW[;W'<^'+-R]I\5;W<\MO1OXF985DC1M''M)+PT(*DZ-(//T$'7
M4@^$U'N;Z-QUEG#MV_6GZTB9^E5AN"@%`*`4!S1S]CZE`=M`*`4!(VW^4#\$
MO[:@)^@%`*`J.1\WTQ0$B1:-3]TNO,_[&%_W]`4TL_PEU_[&%_W]`-+/\)=?
M^QA?]_0$6^FP]LOJ=O75J->F/`(Y#EK)!Y4!T]./_"WOXO;_`)50#IQ_X6]_
M%[?\JH!TX_\`"WOXO;_E5`.G'_A;W\7M_P`JH!TX_P#"WOXO;_E5`.G'_A;W
M\7M_RJ@'3C_PM[^+V_Y50#IQ_P"%O?Q>W_*J`KTV#0_=;UIH=?XO;O>Z>EK_
M`!K7ITY^"A1TZ=WR>@Q_>T;>E]73(R)$CJ^ZFW0[2XUU<=>M+L]IKK\?0?/6
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M+IGULC]6'[94,[9:C_S+<'\QXQ_J"E;_``AYWZ`XZ93VLC]6'[9J1NC$[OZL
MWNQNU^WM:GEJW=LW;,2V^D0@/4&.R[)V9FL:0HEO3JU0-%:Z:CC4QAO._+QY
M(V>7KE*OR1."UF'AMZC<[^YGJ[2->6W9:]E4HW=3^0Q_ZGW;O_Z+?S_DS;7_
M`%Y6S74?JV/UI_LD9R>%?^KJ/_I6/^\2EHB=V%,QOUZ_;Y.,ZC03,2P!B*%>
M`OJA9K(?4C7P``>/A5EQZER[(V?)*7TQ,MB'A/O5SW-1:KTV[*7EI=;-Q-EV
M-H4YQ8%8Q=-P'G@Q<O46YMAQ&-:%(^;9/:]3UNR.6^@AK4IZ6U:JT!T&IJ%S
MGD_EI=XH4IT.5=_6DCO/"\=&6K67@SR7<]:BE"VH^R][C-O=U=INSTV;X:[?
M%H7RNH`]6'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A
M?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!T
MV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM
M\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\K
MH#&NYC*EV=9M]QS^/;PVOYQ1A]EQN9=U-:'K/:7"_P`&6ECHYB,DKTUU.E;>
M&[?>>LH.==G,VE\B:\Y!Z[',>*^YED1L4]?N8PE.G_%.,J?9VFESD;9OM7.U
MO.[G;=HKM>UQK"NU[7J/5VG7EG:=IU<^KCK4_7+IL5KE[94\GJGEW)HM76YG
M<W3[NU7RUN5\^TZ_5ME_[9W:_P"6L)_U92N7PM>>7[)BY-`_ZF;_`.G:_P"X
M9SVM9VV39[B+3<<^=8^<CVJKI9<:CO!WU1G@VF'?Y+:F^C3B2#KX-*BL_O>]
M7>**?+T-OI?%([CPNM/6%<_*2ON'>[>>,$Z\JW<LI*GE,EAO"]>$S+/S99?%
MQYW;3E6CZW4=+[KC/S+TDC';Q#LAI+RDIU/3U6ZS@Z>Q="--:KZW49EW=/TO
MD])PG-X=ZC,[27E(;]5D=91;K,5A'9*ZB@*NB4E>G+4@:T7-5;MYCO\`==S/
MF<N7EX+TF+BSMQJ?_,<]Y_V-C?Z>K:][PCYWZ#G4L#ZU_P#5A^T4[';C^T<]
M_,V-_IZGO>$?._0*8'UK_P"K#]H=CMQ_:.>_F;&_T]3WO"/G?H%,#ZU_]6'[
M0[';C^T<]_,V-_IZGO>$?._0*8'UK_ZL/VAV.W']HY[^9L;_`$]3WO"/G?H%
M,#ZU_P#5A^T.QVX_M'/?S-C7Z>I[WA'SOT"F!]:]^K#]HN3&V<8]<'S#<=P^
MTU';:6;&_4^CA_*^J_=AT^?TO%QK'=K3WBC3M?H-S"5OO?\`VDLCF^S&GE]:
MAF5*+!TIZY-[*]!U$0K<D%6G$A(N"@./@U-:+I79N.H5:>MO.71CWY1?/B=N
M^74*@(Q_P2+Y\3MW[G\>JCIT@P]NDC9HL$9/)O:;T4?Q95GA6E5]2/K2XD7!
M#*F`?!)(2?`:W\/\U7W7L=>XYCQ#_).3_P#8?Q5-G)3O/+T4^T:Z^K[/?VON
MG_RYAO\`JFI:N3PM^>7H.)Y=%^OE_J6_^X/5]GO[7W4_Y<PW_5-*Y/"WYY>@
M<NB_7R_U+?\`W"<QUG8I-T8-VN.XS\77WMRLV.Q8`7J-#+7;+],F*:\8"0/&
M=*Q7GF<GNU!/J;K\J1M82\.K(7YF62[?^J,5&O7R2E*G8;9PT81ZG&^:)-Q%
ML[)'JGS="LYA]GIP[$M7`)\_A\=04^?F?/7FKMK4].Q^X[E?E>7N.CEI3KW'
MHZ,9_*<@^(VS](U:91T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ
M1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H#L0C&N.DG(/!_P"!M@\?_P"P-`<^
MC&ORF_\`Q*V_+Z`=&-?E-_\`B5M^7T`Z,:_*;_\`$K;\OH#W048]VX[.1?"K
MLU>_AVX)TZN/%,XG6@)GILWPUV^+0OE=`.FS?#7;XM"^5T`Z;-\-=OBT+Y70
1%0FS<?NUVY?DT+QC_>Z`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
